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ABSTRACT
MECHANISMS OF SYNAPSE FORMATION AND MAINTENANCE: INSIGHTS FROM THE DEVELOPING AND
DISEASED NERVOUS SYSTEM
Ethan G. Hughes
Rita J. Balice-Gordon, Ph.D.
The formation and maintenance of synapses is essential for the central nervous system (CNS) to
function. In the developing nervous system, the assembly of synaptic circuits is a complex and dynamic
process, requiring the coordinated exchange of signals between pre- and postsynaptic neurons and
surrounding glia. The maintenance and modulation of synaptic connections is required for normal CNS
function and ongoing plasticity. The structural and functional integrity of synaptic connections is often
modified or lost in the diseased nervous system, resulting in profound cognitive and behavioral deficits.
While some aspects of the mechanisms underlying the formation, maintenance and plasticity of CNS
synapses in the developing and diseased nervous system have been elucidated, many more remain to be
understood.
In my thesis work, I have examined the role of astrocytes in the development of GABAergic hippocampal
synapses in in vitro models. I have also examined the maintenance of glutamatergic synapses in in vitro
and in vivo models of anti-NMDAR encephalitis, an immune-mediated disorder of memory and behavior.
First, I demonstrate that secreted factors released from astrocytes specifically increase GABAergic axon
length, branching, and synaptogenesis, that these effects are not mediated by several well-known
candidates, and that the secreted factors from astrocytes are proteins. Second, I examined the identity of
the proteins released from astrocytes that affect GABAergic neurons using size fractionation, mass
spectroscopy, and computational analyses. Third, I examined the cellular and synaptic mechanisms
underlying anti-NMDAR encephalitis and investigated the effects of autoantibodies from patients with this
disorder on the maintenance and function of CNS excitatory synapses. Together, my work extends our
understanding of how neuron-glial communication modulates the formation of synapses in the
developing brain, and how the disruption of synapse maintenance may underlie cognitive deficits in the
diseased nervous system.
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ABSTRACT

MECHANISMS OF SYNAPSE FORMATION AND
MAINTENANCE: INSIGHTS FROM THE DEVELOPING AND
DISEASED NERVOUS SYSTEM
Ethan G. Hughes
Rita J. Balice-Gordon, Ph.D.
The formation and maintenance of synapses is essential for the central nervous
system (CNS) to function. In the developing nervous system, the assembly of synaptic
circuits is a complex and dynamic process, requiring the coordinated exchange of signals
between pre- and postsynaptic neurons and surrounding glia. The maintenance and
modulation of synaptic connections is required for normal CNS function and ongoing
plasticity.

The structural and functional integrity of synaptic connections is often

modified or lost in the diseased nervous system, resulting in profound cognitive and
behavioral deficits. While some aspects of the mechanisms underlying the formation,
maintenance and plasticity of CNS synapses in the developing and diseased nervous
system have been elucidated, many more remain to be understood.
In my thesis work, I have examined the role of astrocytes in the development of
GABAergic hippocampal synapses in in vitro models.

I have also examined the

maintenance of glutamatergic synapses in in vitro and in vivo models of anti-NMDAR

encephalitis, an immune-mediated disorder of memory and behavior. First, I demonstrate
that secreted factors released from astrocytes specifically increase GABAergic axon
length, branching, and synaptogenesis, that these effects are not mediated by several
well-known candidates, and that the secreted factors from astrocytes are proteins.
Second, I examined the identity of the proteins released from astrocytes that affect
GABAergic neurons using size fractionation, mass spectroscopy, and computational
analyses. Third, I examined the cellular and synaptic mechanisms underlying antiNMDAR encephalitis and investigated the effects of autoantibodies from patients with
this disorder on the maintenance and function of CNS excitatory synapses. Together, my
work extends our understanding of how neuron-glial communication modulates the
formation of synapses in the developing brain, and how the disruption of synapse
maintenance may underlie cognitive deficits in the diseased nervous system.
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Introduction
Part 1: Neuron-glia signaling in CNS synapse formation

The assembly of central nervous system (CNS) synaptic circuits is a complex and
dynamic process, requiring the coordinated exchange of signals between pre- and
postsynaptic neurons and surrounding glia. Astrocytes, one of the main glial cell types in
the CNS, have been traditionally considered to act passively in the brain, maintaining
ionic homeostasis in the extracellular milieu, removing neurotransmitters from the
synaptic cleft, and providing trophic factors for neurons. Recently, this view has been
challenged by evidence that astrocytes can respond to and modulate neuronal signaling.
While astrocytes participate in the function of neuronal circuitry, other studies implicate
astrocytes in neuronal process outgrowth and the development and maintenance of
synaptic connections. However, until recently the mechanisms by which astrocytes affect
neurite outgrowth and synapse formation, function and maintenance have been poorly
understood.

Role of astrocytes in neurite outgrowth
The surface of astrocytes and astrocyte precursors are prominent substrates for
neurite growth during development, and also play an active role in directing axons to
targets by both promoting and inhibiting axonal outgrowth. Astrocytes express and
release numerous factors that promote and inhibit neurite outgrowth.
1

Studies

investigating the signals that promote axon growth along astroglia surfaces as in the
developing optic pathway, have identified cell surface adhesion molecules, such as Ncadherin and integrins, to be expressed on the surface of astrocytes promote neurite
outgrowth (Neugebauer et al., 1991).

Interestingly, other cell-surface proteins also

present on astrocytes, such as chondroitin sulfate proteoglycans, have been shown to
restrict neurite outgrowth (Smith-Thomas et al., 1994). In addition to contact-mediated
factors, astrocytes have also been shown to promote neurite outgrowth through the
release of diffusible factors. Biochemical fractionation and purification of astrocyte
conditioned media has identified extracellular matrix proteins, laminin and fibronectin,
are released by astrocytes and act to promote neurite outgrowth (Matthiessen et al.,
1989). Furthermore, astrocytes release trophic factors, such as fibroblast growth factor,
that stimulate both axonal and dendritic growth of dissociated neurons grown in vitro (Le
and Esquenazi, 2002).
How do astrocytes both promote and inhibit neurite outgrowth? First, there may
be regional differences in the ability of astrocytes to modulate neurite outgrowth such
that local astrocytes support outgrowth in a manner distinct from target-derived or other
cues (Qian et al., 1992). Second, populations of astrocytes within the same region of the
nervous system may be composed of functionally distinct subtypes, some of which
support and others that restrict neurite outgrowth (Meiners et al., 1995). Recent work
shows that astrocyte subtypes in the spinal cord are positionally distinct and are
determined by the expression of certain homeodomain transcription factors (Hochstim et
2

al., 2008). Third, neurite promoting properties of astrocytes may be a balance between
the expression of promoting and blocking molecules (Smith-Thomas et al., 1994).
Understanding how astrocytes affect neurite outgrowth will not only give us a better
understanding of how the nervous system develops but also provide insights into the
diseased nervous system, as astrocytic responses to injury are thought to negatively affect
axon regeneration (Benfey and Aguayo, 1982; Smith et al., 1986; Tomaselli et al., 1988;
Silver and Miller, 2004; Rolls et al., 2009). Together, these studies show that astrocytes
use both soluble and contact-mediated mechanisms to both promote and inhibit the
outgrowth of processes from neurons.

Role of astrocytes in the development of synapse structure and function
Several lines of evidence suggest that astrocytes also affect the development of
synapses. First, astrocytes extend thousands of fine processes that enwrap synapses and
blood vessels (Ventura and Harris, 1999; Bushong et al., 2002). Second, the peak of
astrocyte development overlaps with the formation of synapses during the development
in vivo (Ullian et al., 2001). Third, experimental evidence has shown that in purified
retinal ganglion cell cultures, the presence of astrocytes and/or astrocyte conditioned
media (ACM) dramatically increases the number of presynaptic contacts, the quantal size
and efficacy of neurotransmitter release, and the number of postsynaptic AMPA receptor
clusters (Pfrieger and Barres, 1997; Nagler et al., 2001; Ullian et al., 2001; Ullian et al.,
2004). Fourth, astrocyte-like glia in C elegans are important for synapse specification
3

and the source of soluble factors that both increase and decrease synapse formation (Shen
and Bargmann, 2003; Shen et al., 2004; Colon-Ramos et al., 2007; Poon et al., 2008).
These data suggest that astrocytes, in addition their roles in neurite outgrowth, modulate
the formation of synapses in the developing nervous system.

Role of astrocytes in the development of inhibitory synapses
Since a majority of studies investigating synaptogenesis have focused on the
formation of excitatory synapses, much less is known inhibitory synaptogenesis. While
the components of the inhibitory synapse are clearly defined, the mechanisms regulating
the construction of inhibitory synapses are less understood.

Recent studies have

implicated several different processes involving secreted factors, trans-synaptic signaling
molecules, and transcription factors in mediating the formation of inhibitory synapses.
The secretion of the neurotrophic factor BDNF not only increases the formation of
excitatory synapses, but also increases the number of inhibitory synapses formed by
developing neurons (Vicario-Abejon et al., 1998; Marty et al., 2000). The trans-synaptic
adhesion molecule, Neuroligin-2, is localized to inhibitory synapses and induces the
formation of inhibitory presynaptic terminals when expressed in heterologous cells (Graf
et al., 2004; Varoqueaux et al., 2004). In addition, the transcription factor NPAS4
regulates the expression of activity-dependent genes, which in turn control the number of
GABA-releasing synapses that form on excitatory neurons (Lin et al., 2008).

4

Though many studies have investigated the role of astrocytes at excitatory
synapses, the role of astrocyte signaling in inhibitory synapse formation and function is
largely unknown. Astrocytes influence inhibitory synaptic transmission in hippocampal
slices, where perisynaptic astrocytes release glutamate in response to GABAB receptor
activation potentiating interneuron GABA release onto pyramidal neurons (Kang et al.,
1998). Recent work has demonstrated that Bergmann glia of the cerebellum express L1
family immunoglobulin protein Close Homologue of L1 (CHL1) which directs the
innervation of inhibitory stellate cells onto their postsynaptic targets (Ango et al., 2008).
In addition, cortical astrocytes increase the GABA-induced Cl- currents and contribute to
the maintenance of surface GABAA receptors (GABAARs), the major inhibitory
ionotropic receptor, in developing hippocampal neurons (Liu et al., 1996; Liu et al.,
1997). Recent work has shown that astrocytes increase inhibitory synaptogenesis by
augmenting the number of inhibitory presynaptic terminals and frequency of miniature
IPSCs, through the modulation neurotrophin signaling between neurons (Elmariah et al.,
2005). These findings support a role for astrocytes in the formation and function of
inhibitory synapses as well as excitatory synapses, as previously appreciated.

Role of astrocyte-neuron contact in synapse structure and function
The intimate proximity of neurons and astrocytes in the brain raises the question
of what role astrocyte contact plays in synapse formation and function. Astrocytes
ensheathe synapses throughout the hippocampus (Ventura and Harris, 1999) and recent
5

work showed that astrocytes regulate postsynaptic spine morphology through signaling
between ephrinA3 in astrocyte processes and ephA4 in dendritic spines (Murai et al.,
2003). Time-lapse microscopy has revealed that astrocytes rapidly extend and retract
fine processes to engage and disengage motile postsynaptic dendritic spines (Haber et al.,
2006). This activity of astrocytic processes during development can act to stabilize
dendritic filapodia and possibly lead to their maturation into spines (Nishida and Okabe,
2007).
In addition to playing a role in maintaining synaptic structure and number by
regulating spine shape, astrocyte contact is important in the plasticity of synaptic circuits.
In the hypothalamus, withdrawal of astrocyte processes increases the number of synapses
on the postsynaptic neuron (Theodosis and Poulain, 2001).

Astrocyte contact also

increases neuronal voltage-gated calcium currents (Mazzanti and Haydon, 2003), and is
thought to be required for the potentiation of synaptic inputs by D-serine secreted from
astrocytes (Yang et al., 2003).
Beyond roles in regulating synaptic structural and functional plasticity, recent
work has shown that astrocyte contact with neurons increases excitatory synaptogenesis
through an integrin-mediated PKC-dependent mechanism (Hama et al., 2004). These and
other studies highlight the importance the physical interactions of neurons and astrocytes
in regulating synapse formation and function.

Role of astrocyte-derived soluble factors in synapse structure and function
6

Several lines of evidence suggest that astrocytes coordinately modulate the preand postsynaptic development of excitatory synapses by soluble as well as contactmediated factors. Glial-derived soluble and contact factors enhance neurite outgrowth
and synapse formation and function (Pfrieger and Barres, 1997; Ullian et al., 2001; Le
and Esquenazi, 2002; Ullian et al., 2004). In purified retinal ganglion cell and spinal
motor neuron cultures, glia-conditioned medium increased the number of presynaptic
contacts made between neurons, quantal size and the efficacy of transmitter release and
increased the number of postsynaptic AMPA receptor clusters (Pfrieger and Barres, 1997;
Nagler et al., 2001; Ullian et al., 2001; Ullian et al., 2004). Recent work from the BaliceGordon lab has shown that astrocytes also enhance inhibitory synaptogenesis by releasing
soluble factors that enhance BDNF to TrkB signaling in neurons (Elmariah et al., 2005).
Additionally, the secretion of the cytokine tumor necrosis factor-α (TNF-α) from
astrocytes increases postsynaptic efficacy in hippocampal cultures and slices by
regulating the number of surface AMPA receptors (Beattie et al., 2002).
Once mature synapses have formed, astrocytes continue to provide soluble factors
that regulate synaptic transmission. Several studies have shown that neuronal transmitters
evoke the release of soluble factors from astrocytes that in turn modulate excitatory and
inhibitory transmission (Kang et al., 1998; Yang et al., 2003; Zhang et al., 2003; Fiacco
and McCarthy, 2004). These effects are mediated in part by astrocyte factors that are
released via a SNARE-dependent mechanism of vesicular release (Bezzi et al., 2004;
Mothet et al., 2005; Pascual et al., 2005).
7

Role of astrocytes in synapse maintenance
Astrocytes role in synapse formation has been well studied; however, what role
astrocytes play in the maintenance of synapses is less understood. In the peripheral
nervous system Schwann cells, a glial cell type that is essential for the development and
function of neuromuscular junctions (NMJ), are crucial for the maintenance of NMJs.
Schwann cell ablation at NMJs causes reduced synaptic efficacy of motor nerve terminals
and retraction after 1 week showing that Schwann cells are essential for the long-term
maintenance of synaptic structure and function of the adult NMJ (Feng and Ko, 2008).
While the role of astrocytes in the maintenance of CNS synapses has not been
specifically examined, astrocytes have been implicated in playing a role in synapse
elimination. Stevens and colleges have shown that immature astrocytes release a soluble
factor that increases the expression and release of C1q, a protein in the classical
complement cascade, from neurons and possibly microglia. C1q then associates with
synapses and is thought to initiate the complement cascade at unwanted synapses to
mediate synapse elimination (Stevens et al., 2007).
At motor nerve terminals, several candidate molecules are necessary for the
maintenance of NMJs. While collagen IV chains alpha 2 are necessary for the proper
development and function of motor nerve terminals, synapse-specific alpha3-6 (IV)
chains accumulate only after synapses are mature and are required for synaptic maintain
synaptic terminals (Fox et al., 2007). Collagens are an essential part of the extracellular
8

matrix and previously have also been shown to be expressed by astrocytes (Heck et al.,
2003). Future studies examining the role of astrocyte-derived collagens may lead to
insights into how astrocytes affect the maintenance of CNS synapses.

Identification of astrocyte-factors involved in synaptogenesis
Since the initial observations that glia enhance excitatory synaptogenesis (Pfrieger
and Barres, 1997), investigators have been in search for the candidate molecules
mediating these effects. Mauch et al. found that astrocyte-derived cholesterol complexed
to ApoE was both necessary and sufficient to increase the number of functional
presynaptic terminals in retinal ganglion cells (RGC) (Mauch et al., 2001). Recent work
has also demonstrated that thrombospondin-1 and -2 expressed by immature astrocytes
can also increase excitatory synapses between RGCs in vitro and in vivo.

These

immature synapses are presynaptically active but postsynaptically silent, suggesting that
other, as yet unknown, factors may coordinate pre- and postsynaptic maturation
(Christopherson et al., 2005).
Identification of astrocyte factors that regulate synapse formation has been limited
by the lack of characterization of the genes and proteins expressed by astrocytes.
Without efficient purification methods to obtain a sufficiently pure population of
astrocytes, gene array analyses were not possible. Using different purification strategies
approaches, two groups have recently profiled the gene expression of in vitro and in vivo
astrocytes (Lovatt et al., 2007; Cahoy et al., 2008). These “astrocyte transcriptomes”
9

provide a view into the inter-workings of astrocytes and show many interesting pathways
and candidates that can now be examined for their roles in synaptogenesis. Taking a
different approach, several other groups have used proteomic approaches to analyze the
proteins released by astrocytes, or the “astrocyte secretome” (Dowell et al., 2009; Keene
et al., 2009; Moore et al., 2009). Translational profiling approaches (Doyle et al., 2008;
Heiman et al., 2008) and analysis of secreted and membrane-bound molecules by signalsequence trap (Spiegel et al., 2006) may yield even more interesting and useful data if
applied to study astrocytes. These gene and secreted protein profiles of astrocytes will be
invaluable tools in proceeding forward in the identification of new astrocyte factors and
their roles in synapse formation.
With the discovery of larger numbers of new candidates from genomic and
proteomic profiles of astrocytes, the evaluation of these potentially interesting candidates
will be necessary. Several groups have used large-scale screens to identify new molecules
implicated in synapse formation and synapse specificity (Kurusu et al., 2008; Linhoff et
al., 2009). One of these approaches was an unbiased expression screen, where a cDNA
library screen yielded a new family of trans-synaptic molecules that mediate synapse
formation (Linhoff et al., 2009). This type of approach on a large and small scale will be
invaluable to evaluate new candidates identified by the gene expression and secreted
protein profiles of astrocytes.

Conclusions and future directions
10

The studies described above begin to define the cellular and molecular
mechanisms that underlie the communication between neurons and glia that modulates
synapse formation, function and maintenance. Evaluating these newly defined pathways
in intact animals represents an important challenge for future research.

Examining

neuron-glia communication will be critical to understand how synaptic connections are
formed and function in the developing and mature brain and will greatly contribute to
disorders of development such as epilepsy, autism and mental retardation, in which
synapse formation, function, maintenance are aberrant or reduced.

Thesis rationale and goals
Though many studies have investigated the role of astrocytes at excitatory
synapses, the role of astrocyte signaling in inhibitory synapse formation and function is
largely unknown. Previous work from our lab has suggested that astrocytes increase
inhibitory synaptogenesis by modulating postsynaptic GABAA receptors via BDNF to
TrkB signaling (Elmariah et al., 2005). Based on these findings, I examined the effects of
astrocytes on presynaptic aspects of inhibitory synaptogenesis and have identified the
proteins released by astrocytes that affect GABAergic neurons (Chapters 2, 3). Using
biochemical, proteomics, and imaging techniques, I tested the hypothesis that astrocyte
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secreted proteins specifically increase GABAergic axon length, branching, and
synaptogenesis.
My work demonstrates the identity of astrocyte proteins that selectively increase
GABAergic axon length, branching and the density of functional synapses. Moreover, I
show that these proteins differentially affect GABAergic axon outgrowth compared to
glutamatergic neurons. Together this work characterizes new roles for astrocytes in
mediating GABAergic synaptogenesis, highlighting the importance of this glial type in
the development and maintenance of neural circuits.

12

Part 2: Glutamate receptors in immune-mediated encephalitis

Glutamate ionotropic receptors, NMDARs and AMPARs, play essential roles in
synaptic transmission and plasticity and underlie numerous brain functions, including
learning and memory. The dysfunction of NMDA and AMPA receptors has been
proposed to result in several well known cognitive disorders, including schizophrenia and
addiction. However, the mechanisms linking changes in glutamate receptor function to
changes in behavior remain controversial. Recently, two new disorders of behavior and
cognition, anti-NMDAR and anti-AMPAR encephalitis, have been identified and are
mediated by autoantibodies against glutamate receptors (Dalmau et al., 2007; Lai et al.,
2009).

Patient autoantibodies bind to surface glutamate receptors, leading to their

internalization and a decrease in receptor mediated synaptic currents, resulting in
glutamate receptor hypofunction. The reduction or removal of autoantibodies results in a
recovery of behavioral and cognitive dysfunctions suggesting that the blockade of
glutamate receptors by autoantibodies is responsible for observed changes in cognition
and behavior (Dalmau et al., 2008); Hughes et al., in preparation). Thus these new
disorders have the potential to provide important insights into the functional roles of
these receptors in memory, behavior and cognition of the normal and diseased brain.

Autoimmunity to synaptic proteins

13

While there are numerous diseases where synaptic dysfunction correlates to a
neurological condition, autoimmune disorders provide an opportunity to link a defined
disease that causes synaptic dysfunction, to circuit dysfunction and, ultimately,
behavioral dysfunction, and in particular to understand how each recovers once
autoantibodies are reduced or eliminated. In the peripheral nervous system, immunemediated alterations in synaptic structure and physiology are known to cause specific
neurological disorders. Two well known examples are Myasthenia gravis and LambertEaton syndrome (Sanders, 2002; Conti-Fine et al., 2006). Patients with these disorders
develop antibodies that alter the function and density of acetylcholine receptors or
voltage-gated calcium channels, resulting in characteristic muscle weakness due to
synaptic dysfunction. Both of these usually improve with immunotherapy and other
treatments. The autoantibodies that cause these disorders affect synaptic proteins by at
least three different mechanisms. First, they have been shown to functionally block
receptors or channels resulting in decreased synaptic function (Gomez and Richman,
1985; Kim and Neher, 1988). Second, autoantibodies crosslink synaptic proteins which
lead to their removal from the synaptic membrane by internalization and degradation, a
process called antigenic modulation (Drachman et al., 1978; Rich et al., 1994). A third
mechanism is antibody-mediated activation of the complement cascade which has been
shown to cause a large portion of the effects of myasthenia gravis. Autoantibodies bind
the acetylcholine receptor and trigger the complement cascade, which leads to the focal
destruction of postsynaptic membrane through the recruitment of the membrane attack
14

complex (Lennon and Lambert, 1981; Tuzun et al., 2003). While these and other studies
have extensively characterized autoimmune disorders affecting neuromuscular synaptic
proteins, much less is known about autoimmunity to synaptic proteins in the central
nervous system.

Autoimmunity to glutamate receptors
Autoimmunity to glutamate receptors (both NMDA and AMPA receptor subunits)
has been previously described in patients with epilepsy, systemic lupus erythematosus
(SLE) and encephalitis. Autoantibodies against the GluR3 subunit of the AMPA receptor
have been implicated in mediating Rasmussen’s encephalitis, a severe epileptic disorder,
and several other epilepsies (Rogers et al., 1994; Levite and Ganor, 2008), although the
association of GluR3 autoantibodies and encephalitis has been controversial (Pleasure,
2008). Previous work has suggested that some autoantibodies against GluR3 can act as
AMPA receptor agonists and evoke ion currents (Twyman et al., 1995) which can lead to
excitotoxic cell death (Levite et al., 1999). However, other groups have been unable to
find autoantibodies against GluR3 in patients with Rasmussen’s encephalitis and
intractable epilepsy, or, when autoantibodies are present; these antibodies did not affect
AMPA receptor function (Watson et al., 2004). These results suggest that although
GluR3 autoantibodies may have pathogenic effects, their presence is not characteristic of
Rasmussen’s encephalitis or epilepsy.

15

Some studies show that autoantibodies against double-stranded DNA also crossreact to the NR2A or NR2B subunits of the NMDA receptor in SLE (DeGiorgio et al.,
2001). These autoantibodies that bind DNA and the NR2 subunit of NMDA receptors can
cause apoptotic death of neurons in vivo and in vitro through an excitotoxic and
complement-independent mechanisms (DeGiorgio et al., 2001). However, while other
groups have confirmed the presence of NR2 autoantibodies in some patients with SLE,
these studies have not found an association of the presence of autoantibodies and
cognitive dysfunction (Hanly et al., 2006; Harrison et al., 2006; Lapteva et al., 2006).
These findings suggest that although autoantibodies against NR2 subunits exist in some
patients with SLE, however, their function and correlation with SLE is less well defined.
Autoantibodies against the metabotropic glutamate receptor mGluR1 have been
identified in two patients diagnosed with cerebellar ataxia after being in remission from
Hodgkin’s lymphoma (Sillevis Smitt et al., 2000). These autoantibodies have been
shown to reduce the basal activity of Purkinje cells and block induction of long-term
depression (Coesmans et al., 2003).

Another patient with cerebellar ataxia has

autoantibodies to Homer3, an mGluR1 interacting protein (Zuliani et al., 2007). This
work suggests that autoimmunity to synaptic metabotropic proteins may result in
cerebellar dysfunction.
Taken together, these studies suggest that autoantibodies against glutamate
receptors may be present in epilepsy, systemic lupus erythematosus (SLE) and some
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types of encephalitis. However, more work is needed to establish a causative pathogenic
effect of these autoantibodies in mediating the symptoms of these disorders.

Anti-NMDAR encephalitis: Human model of NMDA receptor dysfunction
Recently, a new disorder has been described by Dalmau and colleges where the
presence of autoantibodies against the NR1 subunit of the NMDA receptor confirms the
diagnosis of the behavioral and cognitive dysfunctions associated with the disorder. This
disorder, anti-NMDA receptor encephalitis, is a severe, potentially lethal, but treatment
responsive encephalitis that affects children and young adults, predominantly women,
and manifests with a predictable set of symptoms (Dalmau et al., 2007; Dalmau et al.,
2008); Florance et al., 2009). Two large cohorts of patients comprising 181 cases show
that the disorder presents with sudden behavioral and personality changes for which
patients are often admitted to psychiatric centers and are often misdiagnosed with acute
schizophrenia (Dalmau et al., 2007; Dalmau et al., 2008); Florance et al., 2009). Similar
to autoimmune disorders of the neuromuscular synapse, anti-NMDA receptor
encephalitis may also occur as a paraneoplastic manifestation of a systemic tumor, mostly
commonly ovarian teratomas. Studies show that the frequency of tumor association is
age- and gender-dependant (Florance et al., 2009).

Despite the severity of the

neurological syndrome, 75% of patients respond to immunotherapy and when
appropriate, tumor removal. The recovery occurs over months, with initial resolution of
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the movement and autonomic symptoms, and then gradual improvement of behavioral
and memory deficits.
To investigate the cellular mechanisms underlying the behavioral deficits in antiNMDAR encephalitis, the effects of autoantibodies from patients were examined in in
vitro and in vivo studies of rats. These studies show that autoantibodies decrease the
surface density and synaptic localization of NMDA receptor clusters via antibody
mediated capping and internalization, that the magnitude of these changes depends on
antibody titer, and that these changes are reversible when antibody titer is reduced
(Dalmau et al., 2008); Hughes et al., in preparation). Moreover, patient anti-NMDA
receptor antibodies decrease NMDA but not AMPA receptor mediated synaptic currents,
consistent with selective loss of surface NMDA receptors (Hughes et al., in preparation).
These data show that NR1 autoantibodies reversibly alter the number and distribution of
NMDA receptors in neurons, resulting in a decrease in excitatory synapse function.
Therefore, the recovery seen in human patients may be due to reversible alterations in
glutamate receptor synaptic localization and function without wholesale synapse loss.
Together these results suggest that the cognitive and behavioral deficits in patients are the
result of autoantibodies causing NMDA receptor hypofunction.
Previously, NMDA receptor dysfunction has been implicated in several other
cognitive disorders, including schizophrenia (Olney et al., 1999). Studies investigating
the effects of phencyclidine (PCP) and ketamine, noncompetitive antagonists of NMDA
receptors, in human subjects have shown these drugs induce behaviors similar to the
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positive and negative symptoms of schizophrenia (Luby et al., 1959; Krystal et al., 1994).
In rodents, these same drugs that block NMDA receptor function also induce
schizophrenic-like symptoms (Jentsch and Roth, 1999; Mouri et al., 2007). Furthermore,
mice with reduced NMDA receptor expression show behaviors related to schizophrenia
(Mohn et al., 1999). Interestingly, patients with anti-NMDAR encephalitis show
symptoms such as psychotic behavior, signs of involvement of dopaminergic pathways,
and autonomic instability (Dalmau et al., 2007; Dalmau et al., 2008) that are also caused
by ketamine and PCP and seen in patients with schizophrenia. This suggests that the
symptoms of anti-NMDAR encephalitis patients most likely results from NMDA receptor
hypofunction and may provide new insights into the role of NMDA receptors in behavior
and cognition.

Anti-AMPAR encephalitis: Human model of AMPA receptor dysfunction
Anti-AMPAR encephalitis is another recently identified disorder in which
behavioral and memory deficits are associated with autoantibodies against the GluR1and
2 subunits of the AMPA receptor (Lai et al., 2009). This disease is thought to be a
disorder of learning and memory, as these patients develop seizures and very severe
short-term memory deficits. The median age of the first characterized cohort of 10
patients was 60 years (range 38 - 87); 9 were women; 7 had tumors of the lung, breast or
thymus. Nine patients responded to immunotherapy or oncological therapy but with
frequent neurologic relapses, without tumor recurrence. The presence of neurological
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relapses and their frequency was correlated with neurological outcome of the patient.
None of these patient autoantibodies reacted with GluR3, a subunit identified as an autoantigen in some patients with Rasmussen’s encephalitis (Rogers et al., 1994; Lai et al.,
2009).
To begin to characterize the cellular mechanisms underlying anti-AMPAR
encephalitis, dissociated rat hippocampal neurons were treated with GluR1/2
autoantibodies. GluR1/2 autoantibodies decreased the synaptic localization of AMPA
receptors without affecting overall synapse density. Moreover, as for autoantibodies
from patients with anti-NMDAR encephalitis, these effects were reversible. Although
these disorders share some similar aspects, they are associated with a different clinical
phenotype. Anti-AMPAR encephalitis patients did not have ovarian teratomas,
experienced dyskinesias, autonomic dysfunction, or hypoventilation, which are all
hallmarks of anti-NMDAR encephalitis (Dalmau et al., 2008; Iizuka and Sakai, 2008).
The trafficking of AMPA receptors to and from synapses mediates the long-term
potentiation (LTP) and depression (LTD) of synaptic strength, which are thought to
underlie the cellular basis for learning and memory (Kessels and Malinow, 2009). Since
the major effect of GluR1/2 autoantibodies was on AMPA receptor synaptic localization,
these findings suggest that receptor trafficking/turnover is disrupted in this disorder and
AMPA receptors are moved from the synaptic to the extrasynaptic/intracellular pool
similar to LTD paradigms. We are currently exploring the cellular mechanisms mediating
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the effects of GluR1/2 autoantibodies on neurons and synapse function to gain insight
into the cognitive and behavioral dysfunction in these patients.

New disorders of autoimmunity to synaptic proteins
Through ongoing screening of patients diagnosed with limbic encephalitis,
Dalmau and colleagues have identified several new autoimmune disorders with
autoantibodies against other CNS synaptic proteins. Autoantibodies against GABAB
receptors (15 patients to date), neurexin (1 patient) and a potassium channel accessory
subunit (6 patients) have been found in the serum and CSF (Dalmau unpublished data).
While all of these patients have immune-mediated encephalitis, it is clear that each of
these emerging groups have distinct neurological symptoms and behavioral
manifestations. The generation of animal models of these disorders and further study into
their underlying mechanisms will be required as these studies move forward. Given the
importance of synapses in cognition and behavior, the discovery of these disorders may
provide important human models of synaptic protein dysfunction which may could
provide greater understanding of the function of synapses in human behavior as well as
lead to important advances in the treatment of these patients.

Conclusions and future directions
The identification of anti-NMDAR and anti-AMPAR encephalitis will provide a
greater understanding of the role of glutamate receptors in learning, memory and
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behavior in several different ways. First, the continued generation and examination of
animal models and patients will help to better understand, recognize, and treat this and
other immunological diseases that affect cognitive functions. This is essential because
not only are these disorders fatal if not recognized and treated appropriately, but earlier
treatment results in better patient outcomes (Dalmau et al., 2008). Therefore
understanding the underlying mechanisms may facilitate development of novel
therapeutic strategies that can more easily identify and treat patients. Second, these
disorders provide new human models of glutamate receptor function. Since these
disorders have an identified pathogenic mechanism and their behavioral and cognitive
phenotypes can be reversed, they provide a unique opportunity to study these receptors
and their function in humans. Finally, understanding the mechanisms that result in
behavioral deficits in anti-NMDAR and anti-AMPAR encephalitis may provide new
insights into disease pathways of other psychiatric disorders involving the dysfunction of
glutamate receptors.

Thesis rationale and goals
While the pathogenesis of autoimmune disorders of the peripheral nervous system
has been well defined, the mechanisms underlying the newly identified disorder, antiNMDAR encephalitis, remain poorly understood. Whether this CNS autoimmune
disorder utilizes similar mechanisms as in the PNS to cause its characteristic cognitive
and behavioral deficits is unknown. Previous work from our lab has suggested that
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autoantibodies against the NR1 subunit of the NMDA receptor present in the CSF of
patients with the disorder may mediate the deficits of this disorder (Dalmau et al., 2008).
Based on these observations, I examined the effects of autoantibodies in patients with
anti-NMDAR encephalitis on NMDA receptors in vitro and in vivo (Chapter 4). Using
biochemical, electrophysiology and imaging techniques, I tested the hypothesis that
autoantibodies present in patients with anti-NMDAR encephalitis underlie the cellular
mechanism of this disorder of cognition and behavior.
My work demonstrates that patient anti-NR1 antibodies reversibly alter the
number and distribution of glutamate receptors in neurons, resulting in a decrease in
excitatory synapse function. Moreover, this work has extended our understanding of the
cellular mechanisms underlying anti-NMDAR encephalitis and, in the future, may
facilitate a better understanding of the role of NMDA receptors in learning, memory and
behavior.
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Abstract
Astrocytes modulate the formation and function of glutamatergic synapses in the
CNS, but whether astrocytes modulate GABAergic synaptogenesis is unknown. We
demonstrate that media conditioned by astrocytes, but not other cells, enhanced
GABAergic but not glutamatergic axon length and branching, and increased the number
and density of presynaptically active GABAergic synapses in dissociated hippocampal
cultures.

Candidate mechanisms and factors, such as activity, neurotrophins, and

cholesterol were excluded as mediating these effects. While thrombospondins secreted
by astrocytes are necessary and sufficient to increase hippocampal glutamatergic
synaptogenesis, they do not mediate astrocyte effects on GABAergic synaptogenesis.
We show that the factors in astrocyte conditioned media that selectively affect
GABAergic neurons are proteins.

Taken together, our results show that astrocytes

increase glutamatergic and GABAergic synaptogenesis via different mechanisms and
release one or more proteins with the novel functions of increasing GABAergic axon
length, branching and synaptogenesis.
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Introduction
The development of CNS synapses requires not only the exchange of signals
between pre- and postsynaptic neurons but also communication with adjacent glia.
Astrocytes up-regulate the formation of functional glutamatergic synapses through a
variety of signaling mechanisms; both pre- and postsynaptic effects have been identified
(Mauch et al., 2001; Hama et al., 2004; Christopherson et al., 2005). In purified retinal
ganglion cell cultures, astrocyte-conditioned medium (ACM) dramatically increases the
number of presynaptic contacts made between neurons, the quantal size and efficacy of
neurotransmitter release, and the number of postsynaptic AMPA receptor clusters (Nagler
et al., 2001; Ullian et al., 2001; Ullian et al., 2004). Some of the factors released by
astrocytes that mediate these effects have been identified. Astrocyte-derived cholesterol
complexed to apolipoprotein E (ApoE) increases the number of functional glutamatergic
presynaptic terminals in retinal ganglion cell autaptic cultures (Mauch et al., 2001). In
the cerebral cortex, immature astrocytes express thrombospondins (TSPs), which increase
the number of ultrastructually normal glutamatergic synapses that are presynaptically
active but postsynaptically silent (Christopherson et al., 2005). Thus soluble factors,
including

proteins

and

lipids,

released

by

astrocytes

enhance

glutamatergic

synaptogenesis.
By contrast, little is known about whether and how astrocytes modulate the
development of GABAergic synapses.

In earlier work, astrocytes increase GABA-

mediated currents in neurons prior to synaptogenesis (Liu et al., 1996; Liu et al., 1997),
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but the basis of these effects was not shown. Here we demonstrate that astrocytes
increase glutamatergic and GABAergic synaptogenesis via distinct mechanisms and
release one or more proteins that specifically increase GABAergic axon length, branching
and synaptogenesis.
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Results
Astrocytes selectively increase GABAergic neuron axon length and branching
GABAergic neuron morphology and neurite outgrowth was examined in
hippocampal neurons cultured alone or with astrocytes. At all ages examined, neuron coculture with astrocytes or ACM had a profound effect on the length and branching of
GABAergic axons.

In both culture conditions, GABAergic neurons underwent

significant growth and maturation during the first two weeks in vitro (Fig. 1; Supp. Table
1). In contrast, GAD-negative glutamatergic axons were not significantly longer when
neurons were cultured with astrocytes or ACM relative to neurons cultured alone (Fig. 1;
Supp. Table 1). Cell survival, density, soma size and number and length of primary
dendrites of GABAergic neurons or glutamatergic neurons were similar among all culture
conditions (Supp. Table 1). Thus, while neither glutamatergic nor GABAergic axons
require the presence of astrocytes for growth, astrocyte-derived cues specifically enhance
the outgrowth of GABAergic axons.
GABAergic neurons co-cultured with astrocytes or ACM showed significantly
increased axon branching compared to neurons cultured alone (Fig. 1, Supp. Table 1). In
the absence of astrocytes, most GABAergic axons remained unbranched at 4 div and
exhibited relatively few secondary or tertiary branches at 7 div (Fig. 1; Supp. Table 1). In
contrast, GABAergic neurons cultured with astrocytes or ACM had more complex axonal
arbors than neurons cultured alone during the first 2 weeks in vitro, exhibiting 2 to 3
secondary branches as early as 4 div (Supp. Table 1). These effects on branching were
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not seen for glutamatergic neurons (Fig. 1; Supp. Table 1). These results demonstrate
that astrocytes release soluble factors that increase the length and branching of
GABAergic but not glutamatergic axons.

Astrocytes increase GABAergic synaptogenesis
We next asked whether astrocytes or ACM caused an increase in GABAergic
synaptogenesis by assaying the number of GABAergic synapses per length of
GABAergic axon. Neurons cultured with ACM or astrocytes had ~2-fold more
GABAergic synapses per 20 μm of axon length than did neurons cultured in the absence
of astrocytes (Fig. 2A). ACM increased total GABAergic axon length (sum of the length
of primary, secondary, and tertiary axon branches) by ~3-fold (Fig. 2B) and the total
number of synapses by ~7-fold (Fig. 2C). Thus astrocytes secrete factors that increase
GABAergic synapse density, independent of increasing GABAergic axon length and
branching.

Soluble factors specifically released by astrocytes increase GABAergic axon length,
branching and synaptogenesis
To determine whether these soluble factors are released specifically from
astrocytes, we examined the ability of media conditioned by another cell type - primary
meningeal fibroblasts - to increase GABAergic axon length, branching, and synapse
density. We found that 3 days of treatment with fibroblast conditioned media (FCM) did
29

not significantly affect GABAergic axon length or branching at 4 or 7 div compared to
neurons cultured alone (Supp. Fig. 2 A, B).

Immunostaining for synaptic markers

showed that FCM treatment did not significantly increase GABAergic synapse density at
4 or 7 div compared to neurons cultured alone (Supp. Fig. 2C), assayed by the
colocalization of presynaptic synaptophysin and postsynaptic GABAAR clusters. Taken
together, these results suggest that astrocytes, but not fibroblasts, release factors that
increase GABAergic axon length, branching and synaptogenesis.

ACM increases the number of presynaptically active GABAergic synapses
To determine whether astrocytes also promote the function of newly formed
hippocampal synapses, we examined the number of synapses which were labeled with an
antibody directed to the luminal domain of the vesicular GABA transporter (VGAT),
which can be used to mark the sites of synaptic vesicle release and recycling (Martens et
al., 2008). In neuron-only cultures, there are few GABAergic synapses and both neuronastrocyte co-culture and ACM significantly increase the number of GABAergic synapses
(Fig. 3A, B; see also Fig. 2). The number of GABAergic synapses labeled with the antiVGAT-C luminal antibody (and thus were identified as presynaptically active
GABAergic synapses) also was significantly increased in neuron-astrocyte co-cultures
and ACM, compared to neuron only cultures (Fig. 3C). To examine whether astrocytes
increase the proportion of functional GABAergic synapses in addition to increasing
GABAergic synapse number, we plotted the number of functional GABAergic synapses
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against total GABAergic synapse number per neuron.

Although there are fewer

GABAergic synapses on neurons cultured alone, the same proportion of GABAergic
synapses are functional compared to neurons cultured with astrocytes or ACM (Fig. 3 D).
These data show that astrocytes increase the number but not the proportion of synapses
that are functional. Taken together, these results suggest that soluble factors released by
astrocytes increase the number of GABAergic synapses, and these newly formed
synapses are functional.

The effects of ACM on GABAergic neurons do not require neurotrophin signaling,
action potential activity, or cholesterol
We evaluated several candidate mechanisms mediated by astrocyte soluble factors
that increase GABAergic axon length, branching and synaptogenesis. First, we blocked
action potential activity using TTX which had no effect on GABAergic axon length,
branching, or presynaptic terminal density in neuron-only cultures, and did not alter the
effect of astrocytes or ACM on GABAergic axon length, branching, presynaptic terminal
density (Supp. Fig. 3A). To examine whether neurotrophin signaling mediates the effects
of astrocytes, we scavenged endogenous BDNF or NT3 using TrkB- or TrkC-IgG fusion
protein, which did not prevent the increase in GABAergic axon length, branching, or
presynaptic terminal density in neurons cultured with astrocytes or with ACM compared
to neurons cultured alone at 7 div (Supp. Fig. 3B, see also (Elmariah et al., 2005)).
Finally, we examined the role of cholesterol. We found that cholesterol did not increase
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GABAergic axon length, branching or GABAergic synapse density when compared to
untreated and vehicle treated cultures (Supp. Fig. 3C; see also (Elmariah et al., 2005)).
Parallel cultures of neurons grown on astrocytes showed the expected increase in axon
length, branching, and synapse density. Taken together, these results suggest that the
effects of ACM on GABAergic neurons do not require neuronal activity, are
neurotrophin-independent, and cannot be mimicked by addition of exogenous cholesterol.

Effects of astrocytes on GABAergic neurons are not mediated by TSPs
Recent work has shown that TSPs, in particular TSP-1 and -2, are released by
astrocytes and mediate the increase in glutamatergic synaptogenesis in retinal ganglion
cells in vitro and in vivo (Christopherson et al., 2005). TSPs have also been previously
shown to increase retinal neurite outgrowth (Neugebauer et al., 1991; DeFreitas et al.,
1995); but see (Christopherson et al., 2005). Because much of the work on TSPs has
been done in retinal ganglion cell cultures, we first examined the effects of TSPs on
hippocampal glutamatergic synapse density. Treating neuron-only cultures with purified
TSP-1 increased the number of glutamatergic synapses, by 2-fold at 4 div, mimicking the
effects of ACM on glutamatergic synaptogenesis (Fig. 4E). Moreover, immunodepletion
of endogenously released TSPs from ACM using a combination of antibodies against
TSP-1 and TSP-2 (Supp. Fig. 4) abolished the increase in glutamatergic synapse density
mediated by ACM (Fig. 4E). These results show that TSPs released by astrocytes
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increase hippocampal glutamatergic synaptogenesis in vitro, similar to previous
observations in retinal ganglion cells and cortical neurons (Christopherson et al., 2005).
To examine the role of TSPs on GABAergic axon length, branching and
synaptogenesis, neuron-only cultures were treated with purified TSP-1. TSP-1 treatment
did not significantly increase GABAergic axon length or branching at 7 div compared to
neuron-only cultures, whereas parallel cultures of neurons and ACM showed the
expected increases (Fig. 4A, B). This result shows that TSPs do not mediate these effects
of astrocytes on GABAergic neurons.
We next determined whether TSPs could account for the effects of astrocytes on
GABAergic synapse density. TSP-1 treatment of neuron-only cultures from 1 to 7 div
did not affect the density of VGAT+ presynaptic terminals or postsynaptic GABAAR
clusters per dendrite length, whereas cultures treated with ACM showed the expected
increases (Fig. 4C, D). TSP treatment of neuron-only cultures did slightly increase
GABAergic synapse density. This increase, however, was significantly less than that
observed in neurons treated with ACM (Fig. 4 C, D).

Thus, TSPs may increase the

density of GABAergic synapses, but this does not account for the complete activity in
ACM that increases GABAergic synapse density by ~4-fold.
As an additional test of whether TSPs released by astrocytes increase GABAergic
synapse density, endogenous TSPs were immunodepleted from ACM using a
combination of antisera against TSP-1 and TSP-2 (Fig. 4C, D). The density of
GABAergic synapses in neuron-only cultures at 7 div that were treated from 1 to 7 div
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with TSP-depleted ACM was significantly higher than in untreated neuron-only cultures,
but not significantly different in neuron-only cultures treated with ACM.

Thus, in

contrast to glutamatergic synaptogenesis, TSPs do not appear to be necessary or
sufficient to increase GABAergic synaptogenesis, suggesting that another factor(s)
released

from

astrocytes

increase

GABAergic

axon

length,

branching,

and

synaptogenesis.

Soluble factors released by astrocytes that increase GABAergic axon length, branching
and synaptogenesis are proteins
To further examine how astrocytes tested whether the biological activity of ACM
was sensitive to trypsin.

Astrocytes, ACM, ACM + trypsin inhibitor and ACM +

trypsinized ACM all significantly increased GABAergic axon length, branching, and
synapse density, compared to neuron-only cultures (Fig. 5). In contrast, trypsinized
ACM did not change GABAergic axon length, branching, and the density of GABAergic
synapses compared to neuron only cultures at 7 div. Together, these results show that
factors released by astrocytes that increase GABAergic axon length, branching and
synapse density are proteins.
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Discussion
Here we demonstrate for the first time that astrocytes release proteins that
selectively increase GABAergic axon length, branching and synapse density.
Neurotrophins, neuronal activity, cholesterol and TSPs were eliminated as candidate
mechanisms underlying these effects. These results show that astrocytes utilize different
mechanisms to affect glutamatergic compared to GABAergic neurons. That trypsin
abolishes the effects of ACM on GABAergic neurons shows that astrocytes release
proteins that selectively affect GABAergic neurons, expanding the repertoire of glial
function in the development of neural circuits.

Astrocyte soluble factors increase GABAergic neuron axon length, branching, synapse
formation and function
We report for the first time that astrocytes release proteins that selectively
enhance the development of hippocampal GABAergic neurons by increasing GABAergic
axon length, branching, synapse density and synapse function. In the context of previous
work, our results highlight several important features of astrocyte-neuron signaling
during development. First, astrocytes express and release numerous factors, including
proteins, some of which stimulate neurite outgrowth, including laminin, fibronectin and
N-cadherins, among others (Tomaselli et al., 1988; Matthiessen et al., 1989; Aoyagi et
al., 1994). Recent work suggests that cortical astrocytes also release trophic factors, such
as fibroblast growth factor, that stimulate both axonal and dendritic growth in postnatal
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mouse cortical neurons (Le and Esquenazi, 2002). We found that astrocytes release one
or more proteins that increase GABAergic axon but not dendrite length and branching.
Previously identified proteins have not been shown to differentially increase axon
compared to dendrite length and branching in GABAergic neurons.
Second, astrocytes secrete proteins that differentially modulate glutamatergic compared
to GABAergic axonal projections. We found that astrocytes or ACM did not increase
hippocampal glutamatergic dendrite or axon length or branching, whereas astrocytes and
ACM significantly increased GABAergic axon length and branching. Consistent with
this, retinal ganglion cell neurite length and branching are not affected by astrocytes or
ACM (Ullian et al., 2001). Third, we found that astrocytes increase GABAergic synapse
density in addition to increasing axon outgrowth.

Together with recent studies on

glutamatergic synaptogenesis, these results suggest that astrocyte signaling that
influences axon length and synaptogenesis are separable (Mauch et al., 2001;
Christopherson et al., 2005). Finally, our results show that astrocyte secreted proteins
increase the density of functional GABAergic synapses. These findings are consistent
with previous work which showed that astrocyte soluble factors and contact increased the
number of functional glutamatergic synapses (Ullian et al., 2001; Hama et al., 2004;
Ullian et al., 2004). Thus, our works shows that, while astrocytes have some similar
affects on glutamatergic and GABAergic neurons, they also secrete one or more proteins
that have differential effects that may lead to key differences in the development of these
two cell types.
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The effects of astrocyte soluble factors on GABAergic neurons are not mediated by
action potential activity, neurotrophins, cholesterol or TSPs
While previous studies have reported a decrease in GABAergic synaptogenesis
after chronic blockade of synaptic transmission (Kilman et al., 2002; Hartman et al.,
2006), TTX treatment from 1 to 7 div had no effect on GABAergic synapse number in
neuron-only cultures, and did not alter the effect of ACM on GABAergic synaptogenesis.
These different results might be explained by the developmental ages of neurons when
treated with TTX. In our experiments, activity was blocked from 1 to 7 div, while in
previous studies, activity blockade began on or after 5 div (Kilman et al., 2002; Hartman
et al., 2006). Thus our work suggests that astrocytes increase GABAergic axon length,
branching and synaptogenesis via mechanism(s) that are independent of neuronal activity
during early stages of development.
Neurotrophin and Trk signaling have been shown to modulate neurite outgrowth
(Cohen-Cory and Fraser, 1995; McAllister et al., 1996, 1997) and regulate GABAergic
synapse development (Rutherford et al., 1997; Marty et al., 2000; Seil and DrakeBaumann, 2000; Yamada et al., 2002). Moreover, we previously showed that astrocytes
increase postsynaptic clustering of GABAARs by releasing soluble factors that upregulate BDNF-TrkB signaling among neurons (Elmariah et al., 2005). In the present
work, we found that after scavenging endogenous BDNF and NT3, ACM still increased
GABAergic neuron axon length, branching and presynaptic terminal number. These data
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demonstrate that neurotrophins do not account for the effects of ACM on GABAergic
axon length, branching and presynaptic terminal number.
Mauch et al. (2001) found that astrocyte-derived cholesterol complexed to ApoE
was both necessary and sufficient to increase the number of functional presynaptic
terminals in retinal ganglion cell autaptic cultures. However, recent studies have found
that cholesterol is not sufficient to increase hippocampal glutamatergic synaptogenesis
(Hama et al., 2004), or necessary for retinal ganglion cell glutamatergic synaptogenesis
(Christopherson et al., 2005). We find that the addition of cholesterol does not increase
GABAergic axon length, branching or synaptogenesis. Therefore, we have eliminated
cholesterol as a candidate that mediates the effects of ACM on GABAergic neurons.
TSP-1 and -2 expressed by immature astrocytes increase the number of
glutamatergic synapses between retinal ganglion cells in vitro and in vivo
(Christopherson et al., 2005). While we confirm that TSPs are required for hippocampal
glutamatergic synaptogenesis, exogenous TSPs do not mimic the effects of ACM on
GABAergic neurons. Furthermore, depletion of TSPs from ACM does not abrogate the
effect of ACM on GABAergic synaptogenesis. Thus, TSPs are essential for hippocampal
glutamatergic synaptogenesis but other astrocyte proteins modulate GABAergic axon
length, branching and synaptogenesis.

Importantly, these experiments show for the first

time that hippocampal glutamatergic and GABAergic synaptogenesis are regulated by
different mechanisms.
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We have shown that astrocytes release one or more proteins that selectively
increase GABAergic axon length, branching and the density of functional synapses.
Moreover, we show that these proteins differentially affect GABAergic compared to
glutamatergic neurons. Identifying the proteins that selectively increase GABAergic
axon length, branching, synapse formation and function, and the relevant downstream
signaling pathways, is the focus of ongoing work. Together our results characterize new
roles for astrocytes in mediating GABAergic synaptogenesis, highlighting the importance
of this glial type in the development and maintenance of neural circuits.
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Materials and Methods
Cell cultures
Primary neurons co-cultured with astrocytes were prepared as described
previously (Elmariah et al., 2005), with minor modifications. Briefly, hippocampi were
dissected from embryonic day (E) 18 rats, dissociated in HBSS (Earls Buffered Saline
Solution (EBSS) with MgCl2 and HEPES) containing 1% papain for 20 min., triturated in
BME (Basal Medium Eagle), and plated at 75,000-100,000 cells/ml in Neurobasal
medium (Invitrogen, Grand Island, NY) on poly-L-lysine (1 mg/ml; Sigma, St. Louis,
MO) coated coverslips in 24-well plates. Cells were grown at 37°C, 5% CO2, 95%
humidity in Neurobasal medium plus B27 (Invitrogen) that was changed weekly.
Approximately 15% of the neurons in these cultures have small soma size, less
branched dendritic arbors, and express GAD. We have previously shown that, in our
culture system, activation of GABAARs is depolarizing until 4-5 div; after this time,
activation of GABAARs is hyperpolarizing (Elmariah et al., 2004). Since the experiments
reported here were performed at 4 div and older, for simplicity’s sake, cells and synapses
that express GABA-related markers are referred to as inhibitory.
Primary astrocyte cultures were prepared as described previously (Duan et al.,
2003; Zhang et al., 2003). Briefly, hippocampi were dissected from E18 rats, dissociated
in HBSS containing 0.25% trypsin for 20 min, triturated in BME, and plated in T25
flasks in MMEM (Modified Minimum Essential Medium; Invitrogen) supplemented with
10% heat-inactivated FBS (HyClone, Logan, UT), 2 mM L-glutamine, 14 mM sodium
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bicarbonate, 40 mM D-glucose, 1% sodium pyruvate and 1% penicillin and streptomycin.
Astrocytes proliferated for 10 – 14 days; after reaching confluence, they were rinsed in
cold EBSS and shaken at 260 rpm for 18 - 20 hours in MMEM to remove neurons and
other cells. Purified astrocytes were then plated onto poly D-lysine coated coverslips at
400,000 cells/ml in MMEM.

Medium was changed to Neurobasal medium and

coverslips used for ACM experiments within 1 - 3 days. Coverslips were immunostained
with an antibody against GFAP (Chemicon, Temecula, CA) to assess purity prior to use;
in the experiments described here, > 98% of the cells were GFAP+.
For neuron-only cultures, cytosine arabinoside (Ara-C; 10 μM; Sigma) was added
to cultures 18 – 20 hours after plating to prevent glial proliferation. For neuron-astrocyte
co-cultures, the effects of acutely isolated and mature astrocytes (14 – 21 div) were
compared.

For mature astrocyte co-cultures, neurons were plated onto confluent

monolayers of astrocytes grown on coverslips and maintained up to 21 div in Neurobasal
medium.

For neurons cultured with acute astrocytes, neurons were prepared in

Neurobasal plus B27 supplemented with 5% FBS, 1% L-glutamine, and 1% penicillin
and streptomycin as described above without the addition Ara-C, allowing astrocyte
proliferation. At 4 div, when astrocytes composed approximately 75-80% of cells (N =
35 coverslips), culture media was changed to Neurobasal medium with B27 and cocultures were maintained up to 21 div. No differences were observed in the effects of
acutely isolated and mature astrocytes on GABAergic neuron axon length or branching at
4 div (length: acute 303.9 ± 16.5 (N = 85 neurons), mature 291.7 ± 12.9 (24); # of 2°
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branches: acute 3.24 ± 0.33 (85), mature 3.79 ± 0.41 (24); not significantly different,
Student’s t-test). Thus, acutely isolated astrocyte co-cultures were used for experiments.
For neurons cultured with ACM, neurons were plated in Neurobasal medium that
had been conditioned by astrocytes (14-21 days old) during the previous 72 hours.
Sterile inserts with 3 μm high pore density polyethylene terephthalate membranes
(Becton Dickinson Labware, Franklin Lakes, NJ) were placed into each well, and
coverslips with astrocyte monolayers were inverted 0.9 mm above neurons. Inserts
remained in place for the duration of culture. Neuron-only cultures treated with astrocyte
inserts or ACM both had increased GABAergic axon length, branching and
synaptogenesis that were not significantly different from each other (data not shown);
depending on the experiment, these conditions are interchangeably referred to as ACM.
Cell survival and density were similar among neurons co-cultured with astrocytes or
ACM or cultured alone (data not shown, see (Elmariah et al., 2005)). In addition, neuron
co-culture with astrocytes or ACM produced no change in the number or length of
primary dendrites or in the soma size of GABAergic neurons or glutamatergic neurons
compared to neurons cultured alone (Supp. Table 1).
Primary meningeal fibroblast cultures were prepared from E18 rat meninges,
which were dissociated in 0.25% trypsin for 20 min. and plated in T25 flasks in modified
MMEM supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 14 mM
sodium bicarbonate, 40 mM D-glucose, 1% sodium pyruvate and 1% penicillin and
streptomycin for 4-7 days before use. For neurons cultured with fibroblast conditioned
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media (FCM), neuron-only cultures were plated in Neurobasal medium that had been
conditioned by fibroblasts for 48 hours. Sterile inserts with 3 μm high pore density
polyethylene terephthalate membranes (Becton Dickinson Labware, Franklin Lakes, NJ)
were placed into each well, and coverslips with fibroblast monolayers were inverted 0.9
mm above neurons. Inserts remained in place for the duration of culture. At 1 and 4 div,
neuron cultures were treated with FCM for 3 days, and immunostained at 4 and 7 div.

Immunostaining and confocal microscopy
Coverslips were fixed in 4% paraformaldehyde and 4% sucrose for 15 min.,
permeabilized with cold 0.25% Triton X-100 for 5 min., and blocked in 5% normal goat
serum (Invitrogen) for 1 hour at RT. Triple labeling was performed with combinations of
primary antibodies: A2B5 (1:5 dilution, polyclonal; gift of Dr. J. Grinspan), GAD-6
(1:10, monoclonal; Developmental Studies Hybridoma Bank, Iowa), GalC (1:500,
monoclonal, gift of Dr. Judy Grinspan), GFAP (1:1000, rabbit antiserum; Sigma), MAP2
(1:1000, rabbit antiserum; gift of Dr. V. Lee), synaptophysin (1:200, rabbit antiserum;
NeoMarkers, Fremont, CA), tau (1:1000, rabbit antiserum; gift of Dr. V. Lee), VGAT-N
(1:200, guinea pig antiserum; Synaptic Systems, Goettingen, Germany), VGAT-C (1:200,
rabbit antiserum; Synaptic Systems, Goettingen, Germany), and gephryin (1:200, mouse
antiserum; Synaptic Systems, Goettingen, Germany). Antibodies were visualized after
staining with the appropriate FITC-, TRITC- or CY5-conjugated secondary antibodies
(all used at 1:200, Jackson ImmunoResearch, Inc., West Grove, PA). Immunostaining
43

was performed at 4, 7 and 10 div or later ages in vitro with antibodies against glutamic
acid decarboxylase (GAD), the synthetic enzyme for GABA, to identify GABAergic
neurons, and tau, to visualize axons. Because synaptophysin labels both glutamatergic
and GABAergic synapses, and because GABAARs can be transiently clustered beneath
both types of terminals during development (Rao et al., 2000), immunostaining was
performed at 7 div with antibodies against the presynaptic vesicular GABA transporter
(VGAT) and postsynaptic GABAARs or gephyrin to label GABAergic synapses. Images
were obtained using a confocal microscope (Leica TCS SP2). In each image, laser light
levels and detector gain and offset were adjusted so that no pixel values were saturated in
regions analyzed.

VGAT-C luminal antibody labeling
Labeling was performed as described previously (Martens et al., 2008).
GABAergic synapses were identified as clusters in which VGAT-N terminus and
gephyrin immunostaining were colocalized.

Functional GABAergic synapses were

identified as clusters in which these markers were also colocalized with VGAT-C
terminus immunostaining and thus underwent vesicle recycling during stimulation.

Neurotrophin scavenging and TTX, cholesterol and TSP treatment
Cultures were treated with 2 μg/ml TrkB-IgG, TrkC-IgG or control IgG (gift of
Regeneron Pharmaceuticals, Inc., Tarrytown, NY) to scavenge neurotrophins.
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This

scavenger concentration blocked the neurotrophin mediated increase in postsynaptic
GABAAR clusters (Elmariah et al., 2004, 2005). 1 μM tetrodotoxin (TTX, Sigma) was
used to block action potentials (Elmariah et al., 2004, 2005). Treatments began after the
first day in culture and were replenished every 24 hours until immunostaining was
performed at 4 or 7 div. For experiments investigating the role of cholesterol, neurononly cultures were treated with 10 μg/ml cholesterol (a concentration that increased the
number of glutamatergic presynaptic terminals in retinal ganglion cell autaptic cultures
(Mauch et al., 2001); Sigma) or vehicle (EtOH) from 4 -7 div.

For experiments

investigating the role of TSPs, neuron-only cultures were treated with 5 μg/ml purified
TSP-1 (Christopherson et al., 2005); Haematological Tech., Essex Junction, VT) from 1
to 7 div.

TSP immunodepletion
Confluent purified astrocyte monolayers were washed with EBSS and treated with
serum-free medium (Neurobasal plus B27 supplemented with 1% L-Glutamine, and 1%
penicillin and streptomycin) for 5-7 days. ACM was filtered to remove cell debris and
was concentrated 5-10x on Amicon Ultra columns (3-5 kDa; Millipore, Wilmington,
DE). Fresh ACM was maintained at 4°C for no longer than 7 days prior to use in the
bioassays and other samples were stored at -80°C until use. Concentrated ACM was
incubated with 50 μl protein A beads (Pierce, Rockford, IL) and 50 μl protein G beads
(Amersham, Piscataway, NJ) for 1 hour at RT.
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Beads were washed 1x with PBS

followed by incubation with a cocktail of the following anti-TSP-1 and -2 antibodies: 0.2
μg/ml Ab-8 (rabbit antiserum; Neomarkers); 1 μg/ml Ab-2 (monoclonal; Neomarkers);
10 μl anti-mTSP-1 (monoclonal; gift of Dr. D. Mosher), 10 μl anti-mTSP-2 (monoclonal;
gift of Dr. D. Mosher) overnight at 4º C. Antibody bound beads were washed 3x with
PBS and were added to 300 μl concentrated ACM for 1-3 hours at RT. Beads were spun
down and the supernatant was removed and used as TSP-depleted ACM. To determine
the amount of TSP depletion, a sample was saved for Western blot analysis before
addition to neuron-only cultures. To determine the amount of TSP pulldown, beads were
washed 3 times with PBS, 3 times with PBS plus 0.25 M NaCl, and 3 times with PBS, 50
μl loading dye was added, samples were boiled and analyzed by Western blot.

Trypsinized ACM
Trypsinized ACM was prepared by treating concentrated 1 ml of ACM with 10100 ng of trypsin for 1 hour at 37 degrees followed by 1 hour incubation with equivalent
amount of soybean trypsin inhibitor to stop the enzymatic digestion. SDS-PAGE
followed by silverstain analysis showed that proteins in ACM were digested by trypsin
treatment (data not shown). Neuron-only cultures were treated from 1-7 div with ACM
inserts, ACM media, trypsinized ACM, ACM + trypsin inhibitor or ACM inserts+
trypsinized ACM, then immunostained. Astrocytes, ACM, ACM + trypsin inhibitor and
ACM + trypsinized ACM all significantly increased GABAergic axon length, branching,
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and synapse density, compared to neuron-only cultures showing that there are no
secondary effects of trypsin inhibitor on these cultures (see Fig. 5).

Western blot analyses
Samples of concentrated ACM, TSP-depleted ACM or TSP bound to beads were
resolved by SDS-PAGE, transferred to nitrocellulose membranes and probed with
antibodies against TSP-1 (1.5 μg/ml Ab-2; monoclonal, Neomarkers) or TSP-2 (1:250;
monoclonal, BDTransduction, San Jose, CA) followed by alkaline phosphataseconjugated secondary antibody (1:5000; polyclonal, Applied Biosystems, Foster City,
CA). Signals were visualized using chemiluminescence (WesternStar Detection System,
Applied Biosystems). Films were digitally scanned and signals were quantified using
ImageJ software (available at http://rsb.info.nih.gov/ij/).

Quantification and statistical analysis
For all experiments, 6-15 neurons in each condition were examined on each of 2-3
coverslips in 3-5 independent experiments. Neurons were randomly selected for analysis.
GABAergic neurons were distinguished from glutamatergic neurons by anti-GAD
immunoreactivity.

In a majority of experiments, the number and proportion of

glutamatergic and GABAergic neurons were determined by counting GAD+ and GADneurons in a minimum of 5 randomly chosen fields on each coverslip (750 x 750
microns). To assess neuronal morphology, GAD+ soma diameter was measured and the
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number and length of MAP2+ dendrites and the length of tau+ axons were determined
from confocal fluorescence images using interactive software (MetaMorph, Molecular
Devices, Downingtown, PA; or ImageJ).

The number of immunostained pre- or

postsynaptic clusters was determined from confocal images using interactive software
(MetaMorph or ImageJ). To measure synapse density per axon, the longest neurite which
formed synapses was identified as the axon. Because of limitations of spectral overlap
among secondary antibodies and three fluorescence channels, pre- and postsynaptic
specializations of GABAergic neurons were labeled with VGAT, GABAAR-β3, and
GAD antibodies; tau antibody wasn’t used to specifically label axons. Confocal images
of neurons were threshold automatically using an iterative thresholding technique
(Bergsman et al., 2006), and the number and area of individual clusters were determined
using interactive software (MetaMorph, Molecular Devices, Downingtown, PA; or
custom-written ImageJ macros). Clusters with more than 20% pixel overlap of pre- and
postsynaptic markers were considered colocalized and thus synaptic.
Values for axon length, branch number and cluster number were compared across
conditions using the Kruskal-Wallis nonparametric ANOVA test followed by Dunn’s
pairwise multiple comparison test, unless otherwise indicated. All values are presented
as mean ± s.e.m.
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Figures and Legends

Figure 2.1 Astrocytes selectively increase GABAergic axon length and branching.
Hippocampal neurons were cultured alone, with astrocytes or ACM and were
immunostained at 4, 7, and 10 div with antibodies against tau (red) and glutamic acid
decarboxylase (GAD; green).

(A), GABAergic axon length and branching were

significantly increased in neurons cultured with astrocytes (middle) or ACM (right)
compared to neurons cultured alone (left) at 4 div (Supp. Table 1). Areas within white
boxes are shown below at higher magnification. Note that GAD expression is dimmer in
neuron-only cultures compared to neurons cultured with astrocytes or with ACM, as
represented in these representative figure panels, and confirmed by Western blot analyses
(data not shown). Scale bar = 25 (top), 10 (bottom) μm. (B, C), Quantification of the
effect of astrocytes or ACM on GABAergic axon length (B, left) and branching (B, right)
or on glutamatergic axon length (C, left) and branching (C, right). Asterisk indicates
significant difference compared to neuron-only cultures (p < 0.001).
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Figure 2.2 Astrocyte soluble factors increase GABAergic synapse density.
(A), GABAergic axon length and branching was significantly increased in
neurons cultured alone (left) compared to neurons cultured with ACM (right) at 7 div (see
also Fig. 1, Supp. Table 1). Scale bar = 10 μm. Areas within red boxes, shown to the
right at higher magnification, show presynaptic VGAT (top), postsynaptic GABAARs
(middle) and their colocalization (bottom). Neurons cultured with ACM (right) have a
significantly greater synaptic density than neurons cultured alone (left). Scale bar = 10
μm. (B, C, D), Neurons cultured with ACM have significantly increased GABAergic
synapse density (B), axon and branch length (C) and total number of GABAergic
synapses (D) compared to neurons cultured alone. Asterisk indicates significant
difference (p < 0.05, Student’s t test).
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Figure 2.3 Astrocyte soluble factors increase GABAergic synapse function.
(A),

Neurons cultured with astrocytes of ACM have a significantly greater

number of GABAergic synapses (colocalization of blue and green clusters) labeled by the
VGAT-C luminal antibody (red) after stimulation compared to neurons cultured alone.
Scale bar = 10 μm. (B, C), Quantification of the effect of astrocytes or ACM on
GABAergic synapse density (B) and functional GABAergic synapse density (C).
Asterisk indicates significant difference compared to neuron-only cultures (p < 0.001).
(D), Quantification of the number of GABAergic synapses plotted against the number of
functional synapses per cell. Data from each condition was fit with a straight line (R2 >
0.98).
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Figure 2.4

TSPs do not increase GABAergic axon length, branching, or

synaptogenesis.
Hippocampal neurons were cultured alone, with ACM, with TSP-1, or with TSPdepleted ACM, and were immunostained at 7 div with antibodies against GAD (green)
and tau (red) to label GABAergic axons. (A), GABAergic axon length and branching
were increased in neurons cultured with ACM (middle) but not when neurons were
treated with TSP-1 (right) compared to neurons cultured alone (left) at 4 div. Scale bar =
25 μm. (B), Quantification shows that GABAergic axon length and branching were
significantly increased in neurons cultured with ACM compared to neurons treated with
TSP-1 and neurons cultured alone.

** indicates significant difference compared to

neuron-only cultures (p < 0.001). (C), Hippocampal neurons were cultured alone, with
ACM, with TSP-1, or with TSP-depleted ACM, and were immunostained at 7 div with
antibodies against VGAT (red), and GABAAR β3 subunit (green) to label GABAergic
synapses. An increase in presynaptic VGAT clusters, postsynaptic GABAAR clusters
and GABAergic synapse density were observed at 7 div in neurons cultured with ACM
(middle left) or with TSP-depleted ACM (right) but not when neurons were treated with
TSP-1 (middle right) compared to neurons cultured alone (left). Scale bar = 10 μm. (D),
Quantification of increase in presynaptic VGAT clusters (left), postsynaptic GABAAR
clusters (middle) and GABAergic synapse density (right) per length dendrite in neurons
treated with ACM, TSP-1, or TSP-depleted ACM. Single asterisk indicates significant
difference compared to neuron-only cultures (p < 0.050); ** indicates significant
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difference compared to neuron-only cultures (p < 0.001). (E), Quantification of increase
in glutamatergic synapse number per dendrite length in neurons treated with ACM, TSP1 but not TSP-depleted ACM. ** indicates significant difference compared to neurononly cultures (p < 0.001).
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Figure 2.5 Astrocyte soluble factors are trypsin-sensitive.
Hippocampal neurons were cultured alone, with ACM or with trypsinized ACM and
were immunostained at 4 div with antibodies against GAD and tau to label GABAergic
axons and VGAT to label GABAergic presynaptic terminals. (A, B), GABAergic axon
length and branching (A) and GABAergic synapse density (B) were significantly
increased in neurons cultured with astrocytes (middle) but not with trypsinized ACM
compared to neurons cultured alone (left). Scale bar = 25 (top), 10 (bottom) μm. (C),
Quantification of GABAergic axon length, branching and synapse density in neuron-only
cultures cultured with astrocytes, treated with ACM, trypsinized ACM, ACM + trypsin
inhibitor or ACM + trypsinized ACM. * indicates significant difference compared to
neuron-only cultures (p < 0.001).
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Supplemental Figure 2.1 Soluble factors released specifically from astrocytes
mediate affects on GABAergic neurons.
Hippocampal neurons were cultured alone, with astrocytes conditioned medium
(ACM), or with fibroblast conditioned medium (FCM), and were immunostained at 4 and
7 div with antibodies against GAD (green) and tau (red) to label GABAergic axons. (A) ,
GABAergic axon length and branching were increased in neurons cultured with ACM
(middle) but not when neurons were cultured with FCM (right) compared to neurons
cultured alone (left) at 4 div. Areas within white boxes are shown below at higher
magnification. Scale bar = 25 (top), 10 (bottom) μm. (B), Quantification of the effect of
ACM or FCM on GABAergic axon length (left) and branching (right). Asterisk indicates
significant difference compared to neuron-only cultures (p < 0.001). (C), Hippocampal
neurons were cultured alone, with ACM, or with FCM, and were immunostained at 4 and
7 div with antibodies against presynaptic synaptophysin (red), and postsynaptic GABAAR
β3 subunit (green) to label GABAergic synapses. An increase in the percent of GABAAR
colocalization with synaptophysin was observed at 4 and 7 div in neurons cultured with
ACM (middle) but not when neurons were treated with FCM (bottom) compared to
neurons cultured alone (top). Scale bar = 5 μm. (D), Quantification of the effect of ACM
or FCM on GABAergic synapses. Asterisk indicates significant difference compared to
neuron-only cultures (p < 0.001).
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Supplemental Figure 2.2 Astrocyte affects on GABAergic neurons do not require
action potential activity, BDNF or NT3 signaling or cholesterol.
(A), Hippocampal neurons were cultured alone, with astrocytes, or with ACM,
treated with tetrodotoxin (TTX) were immunostained with antibodies against GAD, tau,
and VGAT. TTX treatment had no effect on GABAergic axon length (top), branching
(middle), or presynaptic terminal density (bottom) in neurons cultured with astrocytes or
ACM compared to neurons cultured alone. Asterisk indicates significant difference
compared to neuron-only cultures (p < 0.001). (B), Hippocampal neurons were cultured
alone, with astrocytes, or with ACM, treated with TrkB-IgG or TrkC-IgG were
immunostained with antibodies against GAD, tau, and VGAT. Compared to control
cultures treated with IgG (2.0 μg/ml final concentration), TrkB-IgG or TrkC-IgG had no
effect on GABAergic axon length (top), branching (middle), or presynaptic terminal
density (bottom) in neurons cultured with astrocytes or ACM at 7 div compared to
neurons cultured alone. Asterisk indicates significant difference compared to neuron-only
cultures (p < 0.001). (C), Hippocampal neurons were cultured alone, with cholesterol or
vehicle were immunostained with antibodies against GAD, tau, VGAT and GABAAR.
Cholesterol treatment had no effect on GABAergic axon length (top), branching
(middle), or GABAergic synapses (bottom) compared to neurons cultured alone. Asterisk
indicates significant difference compared to neuron-only cultures (p < 0.001).
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Supplemental Figure 2.3 TSPs are reduced in immunodepleted ACM.
TSP antibodies were incubated with protein A/G beads, then added to 10-fold
concentrated ACM. After incubation, equivalent samples of TSP-depleted ACM were
compared to ACM incubated with protein A/G beads alone, along with the TSP that was
bound to the beads. (A), Immunoblotting with TSP-1 specific antibodies shows that
TSP-1 is depleted by 80% from ACM, and was bound to protein A/G beads. Asterisk
indicates significant difference (p < 0.05). (B), Immunoblotting with TSP-2 specific
antibodies shows that TSP-2 is depleted by 70% from ACM and remains bound to protein
A/G beads. Asterisk indicates significant difference (p < 0.05).
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Supplemental Table 2.1 Astrocytes increase inhibitory axon length and branching.
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Abstract

Several molecules are released from astrocytes that increase the formation and
function of glutamatergic synapses but the molecules that astrocytes secrete to modulate
GABAergic synaptogenesis are unknown. We demonstrate that media conditioned by
astrocytes can be separated by gel filtration and biologically assayed for effects on
GABAergic axon length, branching and synaptogenesis. We found that gel filtration
fractions containing high molecular mass proteins and protein complexes mediate the
effects of astrocytes on GABAergic axon length, branching and synaptogenesis. The
protein composition of these bioactive fractions was examined using mass spectroscopy
and computational analyses. We show that these fractions contain at least 223 astrocyte
secreted proteins. We selected and ranked 34 of these secreted proteins as candidates of
interest, based on literature searches and biological pathway analysis. I describe the
approaches we are taking to evaluate these candidates as proteins that mediate the effects
of astrocytes on GABAergic axon length, branching, and synaptogenesis. Taken together,
these results show that we have identified a list of proteins that are released from
astrocytes and that may modulate the formation and function of GABAergic circuitry.
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Introduction
The development of CNS synapses requires not only the exchange of signals
between neurons but also communication with adjacent glia. Astrocytes increase the
formation of functional glutamatergic and GABAergic synapses through a variety of
signaling mechanisms including both secreted and contact-mediated factors (Mauch et
al., 2001; Hama et al., 2004; Christopherson et al., 2005). Recently, several factors that
increase excitatory synaptogenesis have been identified. Mauch et al. found that
astrocyte-derived cholesterol complexed to ApoE was both necessary and sufficient to
increase the number of functional presynaptic terminals in retinal ganglion cells (RGC)
(Mauch et al., 2001). Thrombospondin-1 and -2 (TSP) expressed by immature astrocytes
can also increase excitatory synapses between RGCs in vitro and in vivo. These TSP
induced synapses are presynaptically active but postsynaptically silent, suggesting that
other, as yet unknown, factors may coordinate pre- and postsynaptic maturation
(Christopherson et al., 2005).

While astrocyte proteins that increase excitatory

synaptogenesis have been identified, astrocyte factors that increase GABAergic
synaptogenesis remain unknown.
The identification of astrocyte factors that regulate synapse formation has been
limited by the lack of characterization of the genes and proteins expressed by astrocytes.
Two groups have recently profiled the gene expression of astrocytes both in vitro and in
vivo (Lovatt et al., 2007; Cahoy et al., 2008). Several other groups have used proteomic
approaches to analyze the proteins released by astrocytes, or the “astrocyte secretome”
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(Dowell et al., 2009; Keene et al., 2009; Moore et al., 2009). These approaches, in
addition to the newly generated gene and secreted protein profiles of astrocytes, will be
invaluable tools in proceeding forward in the identification of new astrocyte factors and
their roles in synapse formation.
In the results presented here, we use a proteomic approach to separate and identify
proteins released from astrocytes that increase GABAergic axon length, branching, and
synaptogenesis. We show that astrocyte soluble proteins (or protein complexes) of high
molecular weight affect these aspects of GABAergic neurons. Furthermore, we identify
the protein composition of bioactive fractions using mass spectroscopy and
computational analyses. Thirty-four proteins were selected as candidates for further
analysis using literature searches and biological pathway analysis.

I describe the

approaches we are taking to evaluate these candidates as proteins that mediate the effects
of astrocytes on GABAergic axon length, branching, and synaptogenesis.

Taken

together, these results show that we have identified a list of proteins that are released
from astrocytes and that may modulate the formation and function of GABAergic
circuitry.

72

Results
Gel filtration separates ACM proteins by size
We concentrated and separated ACM proteins (and protein complexes) by gel
filtration (a typical chromatogram is shown in Fig. 1A). Silver staining of gel filtration
fractions run on a denaturing SDS-Page gel showed that ACM are separated by size and
individual fractions contain relatively small number of bands (Fig. 1B). The first fractions
collected during gel filtration contained many high molecular weight bands but also
several lower molecular weight bands (Fig. 1B). This indicates that smaller proteins
(possibly contained within high molecular weight protein complexes) are present within
large molecular weight fractions. These results show that proteins and protein complexes
released by astrocytes can be separated based on their molecular weight.

ACM proteins in high molecular weight gel filtration fractions affect GABAergic neurons
In order to begin to characterize the protein(s) released from astrocytes that affect
GABAergic axon length, branching and synaptogenesis, we treated neuron only cultures
of dissociated hippocampal neurons with gel filtration fractions and examined the effects
on GABAergic neurons. To assess whether fractionation by gel filtration affected the
ability of ACM to affect GABAergic neurons, we recombined a small amount of each
fraction into one pool (reconstituted ACM) and treated neuron only cultures.
Reconstituted ACM increased GABAergic axon length, branching and presynaptic
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terminal density to a similar extent as unmodified ACM (Fig. 2). These results show that
ACM proteins retain their biological activity after separation by gel filtration.
To examine the size of the protein(s) that mediate the affects of ACM on
GABAergic neurons, groups of 4 gel filtration fractions were pooled and tested in their
ability to affect GABAergic neurons. Fractions containing proteins ranging in molecular
mass of 2000+-860 kDa increased GABAergic axon length, branching, and presynaptic
terminal density. Additionally, fractions with proteins ranging from 859-360 kDa
increased GABAergic axon length and branching, whereas fractions with proteins
ranging from 25-9 kDa only increased the number of GABAergic axon branches. These
results show that the biological activity mediating the effects of astrocyte conditioned
media on GABAergic neurons was separated into two fractions, a high molecular weight
fraction (2000+ - 860 kDa) and a low molecular weight fraction (25 – 9 kDa), each
having distinct biological activities.

Proteomic evaluation of biologically active gel filtration fractions
Biologically active ACM gel filtration fractions were analyzed by tandem mass
spectrometry (MS/MS) to examine their protein composition. Gel/LC-MS/MS analysis
identified a total of 772 unique proteins from three samples of high molecular weight
ACM gel filtration fractions (Supp. Table 1). To specifically examine secreted proteins
we evaluated the protein identifications using a multi-step computational workflow
involving in silico cellular localization prediction algorithms and functional Gene
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ontology (GO) classification. The computation algorithm SignalP (Bendtsen et al., 2004),
which uses N-terminal signal peptides for subcellular localization prediction, predicted
186 proteins to contain an N-terminal signal peptide. To include secreted proteins that
may lack an N-terminal signal, GO analysis was performed using Cytoscape network
visualization software implementing the BiNGO plug-in. An additional 37 proteins were
classified that lacked an identifiable signal peptide, but had been annotated to the
extracellular region (GO: 5 576) or the cell surface (GO: 9 986).Together, these
computational analyses identified 223 proteins as secreted proteins (Supp. Table 1).
Since fractions 1-8 increased GABAergic axon length, branching and
synaptogenesis (see Fig. 2B), we examined the patterns of separation of secreted proteins
to help narrow the list of potential candidates. From our experimental findings we predict
that the protein(s) responsible for increasing GABAergic axon length, branching and
synaptogenesis would be found in “all fractions” or “not separated” fractions. We found
that 11 and 30 proteins were uniquely identified in pooled fractions 1-4 and 5-8,
respectively, while, 39 proteins were identified in both pooled fractions1-4 and 5-8. The
remaining 143 proteins were not separated into any of these three categories (Fig. 3A).
Biological pathway reconstruction provides powerful tools to analyze genomic
and proteomic profiles (van Baarlen et al., 2008). Ingenuity Pathway Analysis (IPA) is a
software tool that accelerates the identification of cellular pathways or processes by
generating protein networks according to biological and functional categories.

We

selected six pathways identified by IPA as significantly represented in our samples (see
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Fig. 3C) that may be important in neurite extension and synapse formation. Of the 223
secreted proteins, ~70 proteins were identified by IPA to be involved in these selected
pathways. A large portion of these proteins are involved in neurite outgrowth and
adhesion, whereas a smaller number of proteins are involved in axon guidance, long-term
potentiation, glial migration, and synaptogenesis (Fig. 3C).
To prioritize this group of proteins for candidate testing we developed criteria to
characterize and rank these potential candidates. Candidates were excluded if i) they
lacked sufficient evidence of secretion (determined from literature searches, 16
candidates) or ii) the candidate was not found in more than one condition or experiment
(8 candidates). To rank candidates we utilized, i) manual literature searches (presence or
function within neurons or astrocytes) and ii) interest of candidate. Interest of a candidate
was based on known protein function (determined by literature searches). Candidates
were grouped into six categories: low interest, interest, high interest, highest interest,
known candidate (candidate shown to be neuron or glial factor that affects neurite
outgrowth or synaptogenesis), known candidate (candidate shown to be neuron-glial
signaling factor that affects neurite outgrowth or synaptogenesis). Using these four
criteria we identified and ranked 34 candidate proteins released by astrocytes that should
be tested for their effects on GABAergic axon length, branching, and synaptogenesis
(Table 2).

Computational and functional classification of potential candidates
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Recently, two groups have generated a gene expression profile of astrocytes in
vitro and in vivo (Lovatt et al., 2007; Cahoy et al., 2008). This astrocyte transcriptome
provides a view into the global gene expression of astrocytes over development and can
be compared to gene expression profiles of other cell types (see (Cahoy et al., 2008). We
utilized this resource to further characterize the candidates we identified from bioactive
gel filtration fractions (Fig. 3) in astrocytes in vitro, in vivo, and compared to other cell
types. We examined the presence of the candidates in expression profiles (from (Cahoy et
al., 2008) of in vitro, in vivo astrocytes and in vivo neurons. Two potential candidates
were not evaluated in the gene expression profiles generated by Cahoy and colleagues
(Neural cell adhesion molecule, complement component C3). Of the other candidates, 31
of the 32 candidates were expressed by astrocytes in vivo, the remaining candidate was
found to be expressed by astrocytes in vitro (Table 2, presence or absence of gene was
determined by methods described in (Cahoy et al., 2008)). We examined whether
candidates were enriched in astrocytes compared to other cell types and conditions. We
found that 33% of candidates are enriched in astrocytes compared to other cell types
(neurons, oligodendrocytes), 19% are enriched in astrocytes in vitro, and 43% are
enriched in astrocytes in vivo. These results suggest that all of our candidates are present
in astrocytes and many are enriched in astrocytes in vivo.
To examine the difference between gene expression values to that of amount of
secreted protein, we employed semi-quantitative MS based on label-free spectral
counting. This method has been previously used as an effective means to estimate relative
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protein abundance (Old et al., 2005). The number of redundant peptides (spectral counts)
was normalized by the protein molecular weight for each identified protein. When the
normalized spectral counts are compared to gene expression values (obtained from
(Cahoy et al., 2008), some candidates with the highest normalized spectral counts are not
genes that are highly expressed by astrocytes in vitro (examples: fibronectin, tenascin C).
This finding suggests that even low expressed genes can produce large amounts of
protein. Together, these results highlight the importance of the combination of proteomic
and genomic approaches to characterizing the astrocyte genes and potential candidates
for mediating the effects of astrocytes on GABAergic neurons.
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Discussion
Here we demonstrate that astrocyte soluble factors can be separated by size
exclusion chromatography, evaluated in a bioassay and identified by mass spectroscopic
and computational techniques. These studies have generated a vast amount of information
about the proteins that astrocytes release into the extracellular space as well as provided
insights into potential candidate proteins that may mediate the effects of astrocytes on
GABAergic neurons.

Candidates shown to mediate astrocytes effects on excitatory synaptogenesis
In the context of previous work, our proteomic analysis identifies several
candidates known to mediate effects of astrocytes on excitatory synaptogenesis. Our
analysis identified both thrombospondin-1 and -2 in the largest molecular weight gel
filtration fractions; fractions that increased GABAergic axon length, branching, and
synaptogenesis. While thrombospondins (TSPs) are released from astrocytes and increase
excitatory synaptogenesis both in vitro and in vivo (Christopherson et al., 2005), we have
previously shown that TSPs are not required for astrocytes to increase GABAergic axon
length, branching or synaptogenesis (Hughes et al., submitted). We also identified
apolipoprotein E (ApoE), which is important for mediating the effects of astrocyte
cholesterol on excitatory presynaptic release (Mauch et al., 2001). However, we do not
believe that ApoE mediates the effects of cholesterol to increase GABAergic
synaptogenesis because we have shown that exogenous cholesterol does not increase
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GABAergic synaptogenesis (Elmariah et al., 2005), see also (Hama et al., 2004;
Christopherson et al., 2005). Two other candidates identified in our evaluation of
bioactive gel filtration fractions are SPARC and SPARC-L1. Both SPARC and SPARCL1 are released from glia and increase neurite outgrowth (Au et al., 2007) and recently
have been implicated in inhibiting and promoting excitatory synaptogenesis respectively
(Eroglu et al., 2007). Since SPARC-L1 increases excitatory synaptogenesis, we tested
whether SPARC-L1 also increased inhibitory synaptogenesis. We added recombinant
SPARC-L1 to neuron-only cultures and found no significant increases in GABAergic
axon length, branching, or synaptogenesis (EGH and RBG unpublished observations)
suggesting that SPARC-L1 does not mediate the affects of astrocytes on GABAergic
neurons. Together, these findings suggest that proteins released from astrocytes that
affect GABAergic neurons have not been previously implicated in mediating the effects
of astrocytes on excitatory synaptogenesis.

Potential candidates for mediating the effects of astrocytes on GABAergic neurons
One potentially interesting candidate identified in the large molecular weight
fractions that increase GABAergic axon length, branching and synaptogenesis is close
homologue of L1 (CHL1). CHL1 is a transmembrane molecule that also can function as a
soluble factor as it can be cleaved from the cell surface by metalloproteases (Naus et al.,
2004). CHL1 is expressed by Bergmann glia in the cerebellum and organize inhibitory
synapses onto Purkinje cell dendrites (Ango et al., 2008). CHL1-deficient mice have
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increased numbers of inhibitory synapses and enhanced inhibitory synaptic transmission
(Nikonenko et al., 2006). Together, these results suggest that CHL1 is important for the
regulation of inhibitory synapse formation and function in the developing nervous system
and make it an important candidate to evaluate whether it is mediating the effects of
astrocytes on GABAergic neurons.
Another interesting candidate identified in bioactive gel filtration fractions is
amyloid beta precursor protein (APP). APP has been intensively studied for its role in
the pathogenesis of Alzheimer’s disease, while its normal function is less understood.
APP is an integral membrane protein expressed in neurons and glia which can undergo
proteolytic processing to release soluble ectodomains. These soluble ectodomains are
important for regulating neurite outgrowth during development (Qiu et al., 1995; YoungPearse et al., 2008) and play roles in modulating synaptic transmission, by increasing the
surface stability of NMDA receptors (Hoe et al., 2009b). Since APP is expressed by
astrocytes and play roles in neurite outgrowth and synaptic transmission, it is another
important candidate to determine whether it plays a role in mediating the effects of
astrocytes on GABAergic neurons during development.
One alternative possibility is that multiple proteins interact to exert the effects of
astrocytes on GABAergic neurons. Since only one large molecular weight fraction
increases GABAergic axon length, branching, and synaptogenesis, this argues that the
bioactive protein(s) are at least separated into the same gel filtration fraction. However,
two proteins identified in this bioactive fraction, amyloid precursor protein (APP) and
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Reelin, interact to increase neurite outgrowth (Hoe et al., 2009a). Other proteins found in
bioactive fractions, such as TSP-1, ApoE, and VLDL, interact to play roles in neuronal
migration (Blake et al., 2008). This evidence suggests that protein interaction and
biological pathway analysis tools should be used to identify sets or pathways of proteins
that could be tested to determine whether they regulate the ability of astrocytes to
increase GABAergic axon length, branching and synaptogenesis.

Evaluating candidates and their affects on GABAergic neurons
With the discovery of large numbers of new candidates from genomic and
proteomic profiles of astrocytes, the evaluation of many potentially interesting candidates
will be necessary. Several groups have used large-scale screens to identify new molecules
implicated in synapse formation and synapse specificity (Kurusu et al., 2008; Linhoff et
al., 2009). One of these approaches was an unbiased expression screen, where a cDNA
library screen yielded a new family of trans-synaptic molecules that mediate synapse
formation (Linhoff et al., 2009). This type of approach on a large and small scale will be
invaluable to evaluate large numbers of new candidates identified by the gene expression
and secreted protein profiles of astrocytes.
We report the identification of astrocyte soluble proteins in gel filtration fractions
that increase GABAergic axon length, branching, and presynaptic terminal density. Of
the 223 identified secreted proteins we intend to focus on 34 candidates based on
biological pathway analysis and literature searches. We plan to screen these candidates
82

individually by treating neuron only cultures with three different concentrations of the
recombinant protein for three days and immunostaining these coverslips for GAD and
VGAT to identify GABAergic neuron neurite morphology and presynaptic terminal
density. In this manner, we will be able to evaluate these 34 candidates in a relatively
short period of time. However, despite the reduction in secretome complexity and
activity-based secretome fractionation using gel filtration, we cannot exclude the
possibility that the biologically active proteins were not identified below the detection
limits of the proteomic approach. Based on the initial candidate protein screen, the
proteomics approach may require further optimization for increased depth of secretome
analysis.
In the results presented here, we use a proteomic approach to separate and identify
proteins released from astrocytes that increase GABAergic axon length, branching, and
synaptogenesis. The studies described above begin to define the cellular and molecular
mechanisms that underlie how astrocytes modulate GABAergic synapse formation,
function and maintenance. These studies will be essential to understanding neuron-glial
communication and the role in play in the development of neural circuits.
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Materials and Methods
Cell cultures
Primary hippocampal neuronal cultures are prepared as previously described (Goslin
et al., 1988). Hippocampi are dissected from embryonic day 18-19 mice, dissociated in
Ca2+- and Mg2+-free HBSS containing 0.03% trypsin for 20 min., triturated in Dulbecco’s
Modified Eagle Medium (DMEM; Life Technologies) supplemented with 10% heatinactivated fetal bovine serum (FBS) and plated at 100,000 cells per ml in DMEM
supplemented with 10% FBS, 10% Ham’s F12 (Life Technologies), and 1% Penicillin
and Streptomycin (Life Technologies) on poly-L-lysine (PLL) coated coverslips in 12well plates. For pure neuronal cultures, cytosine arabinoside (Ara-C; 10 μM) is added to
cultures 18 – 20 hours after plating to prevent glial proliferation. Culture media is
changed to Neuralbasal (Life Technologies) supplemented with B27 (Life Tech.) at 4 div.
Cells are maintained at 37 °C, 5% CO2, 95% humidity; medium is changed weekly.
Primary astrocyte cultures are prepared as described previously (Duan et al., 2003;
Zhang et al., 2003). Briefly, hippocampi are dissected, rinsed in cold HEPES-buffered
Earle’s Balanced Salt Solution (EBSS), dissociated in 0.125% trypsin for 20 min., and
plated in T25 flasks in modified Minimum Essential Medium (MMEM) supplemented
with 10% heat-inactivated FBS, 2 mM L-glutamine, 14 mM sodium bicarbonate, 40 mM
D-glucose, 1% sodium pyruvate and 1% Penicillin and Streptomycin.

Astrocytes

proliferate for 14 – 21 days; after reaching confluency, are rinsed in cold EBSS and
shaken at 260 rpm for 18 - 20 hours in MMEM to remove neurons and other cells.
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Purified astrocytes are then plated onto PLL-coated coverslips at 400,000 cells/ml in
MMEM. Medium is changed to Neuralbasal Medium and coverslips used for neuron cocultures or ACM treatments within 1 - 3 days. Coverslips are immunostained with an
antibody against GFAP (Chemicon) to assess purity prior to use.
For pure neuronal cultures treated with ACM, neurons are plated in Neuralbasal
Medium conditioned by astrocytes or fibroblasts (14-21 days old) during the previous 2472 hours. Sterile inserts with 3 μm high pore density membranes (BD Labware) were
placed into each well, and coverslips with astrocyte monolayers were inverted 0.9 mm
above neurons. Inserts remain in place throughout the culture duration.

Immunostaining and confocal microscopy
Coverslips were fixed in 4% paraformaldehyde and 4% sucrose for 15 min.,
permeabilized with cold 0.25% Triton X-100 for 5 min., and blocked in 5% normal goat
serum (Invitrogen) for 1 hour at RT. Triple labeling was performed with combinations of
primary antibodies:

GAD-6 (1:10, monoclonal; Developmental Studies Hybridoma

Bank, Iowa), GFAP (1:1000, rabbit antiserum; Sigma), tau (1:1000, rabbit antiserum; gift
of Dr. V. Lee), and VGAT-N (1:200, guinea pig antiserum; Synaptic Systems,
Goettingen, Germany). Antibodies were visualized after staining with the appropriate
FITC-, TRITC- or CY5-conjugated secondary antibodies (all used at 1:200, Jackson
ImmunoResearch, Inc., West Grove, PA). Immunostaining was performed at 4, 7 and 10
div or later ages in vitro with antibodies against glutamic acid decarboxylase (GAD), the
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synthetic enzyme for GABA, to identify GABAergic neurons, and tau, to visualize axons.
Images were obtained using a confocal microscope (Leica TCS SP2). In each image,
laser light levels and detector gain and offset were adjusted so that no pixel values were
saturated in regions analyzed.

Quantification and statistical analysis for confocal images
For all experiments, 6-15 neurons in each condition were examined on each of 2-3
coverslips in 3-5 independent experiments. Neurons were randomly selected for analysis.
GABAergic neurons were distinguished from glutamatergic neurons by anti-GAD
immunoreactivity.

In a majority of experiments, the number and proportion of

glutamatergic and GABAergic neurons were determined by counting GAD+ and GADneurons in a minimum of 5 randomly chosen fields on each coverslip (750 x 750
microns). The number of immunostained presynaptic clusters was determined from
confocal images using interactive software (custom-written ImageJ macros). Confocal
images of neurons were threshold automatically using an iterative thresholding technique
(Bergsman et al., 2006), and the number and area of individual clusters were determined
using interactive software (custom-written ImageJ macros). Clusters with more than 20%
pixel overlap of pre- and postsynaptic markers were considered colocalized and thus
synaptic.
Values for axon length, branch number and cluster number were compared across
conditions using the Kruskal-Wallis nonparametric ANOVA test followed by Dunn’s
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pairwise multiple comparison test, unless otherwise indicated. All values are presented
as mean ± s.e.m.

Gel filtration
Concentrated ACM is filtered through 0.22 µm membranes, and injected on the
HPLC for gel filtration analysis using an Agilent (Palo Alto, CA) 1100 series HPLC
controlled by ChemStation software (Agilent). 1.2 mg of ACM in a total volume of 250
µl is resolved onto a Superdex 200 HR10/30 column (GE Healthcare Bio-Sciences,
Uppsala, Sweden) for size exclusion chromatography (SEC) analysis. ACM proteins are
resolved at a flow rate of 0.3 ml/min in 25 mM HEPES, pH 7.25, and 150 mM NaCl.
Fractions (0.5 ml) are collected and concentrated with 5000 NMWL Ultrafree-MC filters
(Millipore). The gel filtration column is calibrated using the following mixture of
globular proteins standards: thyroglobulin (669 kDa, 85 Å), ferritin (440 kDa, 61 Å),
catalase (232 kDa, 52.2 Å), aldolase (158 kDa, 48 Å), albumin (67 kDa, 35.5 Å),
ovalbumin (43 kDa, 30.5 Å), chymotrypsin (25 kDa, 20.9 Å), and ribonuclease A (13.7
kDa, 16.4 Å). The void volume is determined from the elution migration of blue dextran
(2000 kDa, 99 Å). Protein elution is monitored by UV absorbance at 275 nm. All
experiments involving gel filtration chromatography are performed initially at RT.
Fractionated samples are stored at -80 °C until use. Neurons are treated with fractions
diluted 1:20 in NeuralBasal medium and assayed after 72 hours.
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Electrospray Tandem MS Analysis of Astrocyte-conditioned Media
Tryptic digests of fractions from gel filtration (prepared as described in Zuo and
Speicher, 2000) are analyzed on an LTQ linear IT mass spectrometer (Thermo Electron)
coupled with a NanoLC pump (Eksigent Technologies, Livermore, CA) and autosampler.
Tryptic peptides are separated by RP-HPLC on a nanocapillary column, 75 μm id x 20
cm PicoFrit (New Objective, Woburn, MA, USA), packed with MAGIC C18 resin, 5 μm
particle size (Michrom BioResources, Auburn, CA). Solvent A is 0.58% acetic acid in
Milli-Q water, and solvent B is 0.58% acetic acid in acetonitrile (ACN). Peptides are
eluted into the mass spectrometer at 200 nL/min using an ACN gradient. Each RP-LC
run consists of a 10 min. sample load at 1% B; a 75 min. total gradient consisting of 1–
28% B over 50 min., 28–50% B over 14 min., 50–80% B over 5 min., 80% B for 5 min
before returning to 1% B in 1 min. To minimize carryover, a 36 min. blank cycle is run
between each sample. Hence, the total sample-to-sample cycle time is 121 min. The
mass spectrometers are set to repetitively scan m/z from 375 to 1600 followed by datadependent MS/MS scans, the ten most abundant ions with dynamic exclusion enabled.

Protein Identification and Validation
Proteins are identified from the MS/MS spectra using the SEQUEST Browser
program (Thermo Electron). DTA files are generated from MS/MS spectra using an
intensity threshold of 5000 and minimum ion count of 30. The DTA files generated are
processed by the ZSA, CorrectIon, and IonQuest algorithms of the SEQUEST Browser
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program,

and

searched

against

the

NCBI

non-redundant

protein

database

[www.ncbi.nlm.nih.gov/RefSeq/]. Databases are indexed with the following parameters:
average mass range of 500–3500, length of 6–100, tryptic cleavages with 1 internal
missed cleavage sites, static modification of Cys by carboxyamidomethylation (+57 Da),
and variable modification of methionine (+16 Da). The DTA files were searched with a
2.5 Da peptide mass tolerance and 0 Da fragment ion mass tolerance.
Potential sequence-to-spectrum peptide assignments generated by SEQUEST are
loaded into Scaffold (version Scaffold-01_06_17, Proteome Software Inc., Portland, OR)
to validate MS/MS based peptide and protein identifications as well as to compare
protein identifications across experimental conditions. Peptide and protein probabilities
were calculated by the Peptide and Protein Prophet algorithms, respectively. A protein
identification is accepted if it meets one of the following three criteria: (1) ≥ 99.0%
protein confidence and ≥ 3 unique peptides at 95% probability, (2) ≥ 99.0% protein
confidence, 2 peptides at ≥ 50% probability, and satisfied (1) in another condition, or (3)
≥ 99.0% protein confidence, 1 peptide at ≥ 50% probability, and satisfied (1) in a
biological duplicate. Proteins identifications not assigned are manually inspected.
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Figures and Legends

Figure 3.1

Proteins in astrocyte conditioned media are separated based on

molecular weight by gel filtration.
(A), UV spectra of eluted protein as astrocyte conditioned media was separated by
size exclusion chromatography. Fractions (0.5 ml) were collected at the indicated times.
Pooled (B) and individual (C) fractions (2.0 μl) were examined by SDS-Page followed by
silver stain analysis.
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Figure 3.2 Large molecular weight gel filtration fractions increase GABAergic axon
length, branching and synaptogenesis.
Hippocampal neurons were cultured alone, with astrocytes, ACM, or pooled gel
filtration fractions for 3 days were immunostained at 4 div with antibodies against tau
(red) and glutamic acid decarboxylase (GAD; green) and vesicular GABA transporter
(VGAT, blue). (A), GABAergic axon length, branching, and presynaptic terminal density
were significantly increased in neurons cultured with reconstituted ACM (far left) and
high molecular weight fractions (middle left) compared to neurons cultured with midrange molecular weight fractions (middle right) at 4 div. GABAergic axon branching was
significantly increased in neurons cultured with low molecular weight fractions (far right)
compared to neurons cultured with mid-range molecular weight fractions (middle right)
at 4 div. Areas within white boxes are shown below at higher magnification. Scale bar =
25 (top), 10 (bottom) μm. (B), Quantification of the effect of astrocytes, ACM,
reconstituted ACM, or ACM gel filtration fractions on GABAergic axon length (white),
branching (black) or presynaptic terminal density (gray). Asterisk indicates significant
difference compared to neuron-only cultures (p < 0.001).
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Figure 3.3 Proteomic evaluation of biologically active gel filtration fractions
(A), Mass spectroscopic analysis of bioactive fractions yielded approximately 800
proteins. Using a multi-step computational workflow we identified approximately 225 of
these proteins to be secreted. (B), Histogram of the number of secreted proteins present in
all fractions analyzed, only in fractions 1-4, or only in fractions 1-8. (C), The number of
secreted proteins included identified by IPA to be important in six pathways important in
neurite extension and synapse formation.
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Table 3.1 Potential candidates of secreted astrocyte proteins that may mediate the
effects of astrocytes on GABAergic neurons.
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Supplemental Table 1 Mass spectroscopic and computational analyses of biological
active ACM gel filtration fractions.
An interactive excel spreadsheet containing all proteins identified by mass
spectroscopic analysis.
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Abstract
Autoimmunity to synaptic proteins is the cause of well known disorders of
neuromuscular transmission, such as myasthenia gravis and Lambert-Eaton syndrome,
but it is much less known as cause of central nervous system disorders. We recently
described a severe, potentially lethal, but treatment responsive encephalitis associated
with autoantibodies to the N-terminal extracellular domain of the NR1 subunit of the Nmethyl-D-aspartate (NMDA) receptor. This disorder predominates in young women and
children who develop a predictable set of symptoms, including prominent psychosis,
bizarre behavior, and memory deficits, and frequently have an underlying tumor (mostly
ovarian teratoma) that expresses NMDA receptors. Symptoms often respond to
immunotherapy or tumor removal, suggesting an immune-mediated pathogenesis. Here
we demonstrate, using in vitro studies, that patients’ antibodies cause a decrease of
surface density and synaptic localization of NMDA receptor clusters via antibody
mediated capping and internalization. The magnitude of these changes correlates with
antibody titer, and the effects are reversed when antibody titer is reduced. Moreover,
patients’ antibodies decrease NMDA but not AMPA receptor mediated synaptic currents,
consistent with a selective loss of surface NMDA receptor clusters. We also demonstrate
using in vivo studies that NMDA receptor cluster density is dramatically reduced in the
hippocampus of rats infused with patients’ antibodies as well as in the brain of autopsied
patients with this disorder. These studies establish the cellular mechanisms by which
antibodies of patients with anti-NMDA receptor encephalitis alter NMDA receptor
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density, localization and function, which are critical for learning, memory and other
behaviors.
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Introduction
Synaptic plasticity is thought to underlie mechanisms of memory, learning, and
cognition. Central to these neurological functions is the proper synaptic localization and
trafficking of the excitatory glutamate NMDA and AMPA receptors. The roles of these
receptors at the synaptic and cellular levels have been established through animal models
in which the receptors have been genetically or pharmacologically altered (Jentsch and
Roth, 1999; Mouri et al., 2007). In humans the role of these receptors in memory,
learning, cognition and psychosis comes from more indirect approaches, such as
pharmacological trials (e.g., NMDA receptor antagonists causing psychosis), and analysis
of brain tissue from patients with Alzheimer’s disease or schizophrenia in which several
molecular pathways causing a downstream alteration of glutamate receptors are affected.
We recently identified a disorder in which the NR1 subunit of the NMDA receptor is
directly targeted by autoantibodies (Dalmau et al., 2007; Dalmau et al., 2008). Patients
develop prominent psychiatric and behavioral symptoms, rapid memory loss, seizures,
abnormal movements (dyskinesias), hypoventilation, and autonomic instability. In two
series comprising 181 cases, there was a strong female predominance (ratio 8.5:1.5) and
the median age of the patients was 19 years (23 months-75 years; 40% children). Most
patients presented with bizarre behavior, agitation, delusions, hallucinations and
catatonia, leading to admissions to psychiatric centers for suspected psychosis or
schizophrenia. In 55% of the adults (less frequently in children), the disorder appears to
be triggered by the presence of a tumor, mostly an ovarian teratoma that contains nervous
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system tissue and expresses NMDA receptors. Despite the severity of the symptoms 75%
of patients recover after receiving immunotherapy and, when appropriate, tumor removal,
and 25% are left with memory and cognitive deficits, impulsiveness, inappropriate
behavior, or, rarely, die of the disorder. The autoantibodies are present in patients’ serum
and cerebrospinal fluid (CSF), the latter usually showing intrathecal synthesis and high
antibody concentration. All patients’ antibodies recognize the N-terminal extracellular
domain (amino-acid residues 25-380) of NR1, suggesting an antibody-mediated
pathogenesis. We previously showed that patients’ antibodies cause a decrease in surface
NMDA receptor cluster density, but the underlying mechanisms were unexplored. Here
we report in vitro and in vivo studies that establish the cellular mechanisms by which
patients’ antibodies lead to a reduction in surface and synaptic NMDA receptor density
and function, likely underlying the learning, memory and other behavioral deficits
observed in patients with anti-NMDA receptor encephalitis.
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Results

Patients’ antibodies reduce surface NMDA receptor clusters and protein in a titer
dependent fashion
Rat hippocampal neurons were cultured for 14 days were treated 1 day with CSF
or purified IgG containing anti-NR1 antibodies determined by ELISA (Dalmau et al.,
2007) from 10 patients, followed by immunohistochemical and Western blot analyses of
surface and total NR1 protein. Patients’ antibodies decreased NR1 or NMDA receptor
surface and total cluster density in a titer dependent fashion, compared to CSF or IgG
from control patients (Fig. 1A, C). Similar results were obtained with Western blot
analyses of cell surface and total NR1 protein (Fig. 1B, D). Moreover, Western blot
analyses of the effect of patients’ antibodies on NR2 subunits (which assemble with NR1
to form NMDA receptors) showed that patients’ antibodies decreased surface and total
NR2A and NR2B proteins in a titer dependent fashion (Supp. Fig. 1).
To determine whether the effects of patients’ antibodies correlate with the change
of titers during the course of the disease, hippocampal neurons were cultured with CSF
samples obtained at two different time points of the disease of three patients. The initial
CSF was obtained at the time of symptom presentation and the second sample during
symptom improvement in two patients and symptom worsening in the third patient. In the
first two patients the CSF obtained at symptom presentation had a higher NR1 antibody
titer than the CSF obtained during symptom improvement, while in the third patient the
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CSF obtained during symptom worsening had a higher antibody titer than the CSF
obtained at symptom presentation. In all 3 patients, the CSF with higher NR1 antibody
titer decreased NMDA receptor surface and total cluster density (or total NMDA receptor
protein measured by Western blot) (Fig. 1E, F) to a greater extent than the CSF with the
lower titer. Together, these results show that NR1 antibodies from patients with antiNMDA receptor encephalitis decrease NMDAR surface cluster density and protein in a
titer-dependent manner and that in each individual the effects of the antibodies vary with
the change of titers during the course of the disease.

Patients’ antibodies reversibly reduce synaptic NMDA receptor clusters without
affecting the number of synapses and other synaptic components
Because patient antibodies decreased overall NMDA receptor surface cluster
density and protein, we determined whether the antibodies also affected NMDA receptor
synaptic localization, the number of synapses, and other synaptic components.
Hippocampal neurons were cultured with CSF or purified IgG for 3 or 7 days, followed
by immunostaining or Western blot analysis of NR1 and synaptic components such as
presynaptic VGlut, postsynaptic PSD-95, AMPA receptor subunits GluR1 and GluR2,
and GABA receptors. Patients’ antibodies did not affect the number of excitatory
synapses compared to controls (Fig. 2A, B). Moreover, patients’ antibodies did not affect
the density of postsynaptic PSD-95, GluR1, GluR2 or GABA receptor clusters, or the
surface or total amount of these proteins (Supp. Fig. 2), dendritic branching, dendritic
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spine density (Supp. Fig. 3, 4), or cell survival (Supp. Fig. 8). These results show that
patient antibodies specifically affect NMDA receptors without affecting AMPA or
GABA receptors, other synaptic proteins, the number of excitatory synapses, and
neuronal morphology or viability.
While the overall structural integrity of excitatory neurons and synapses was not
affected, we found that patients’ antibodies dramatically reduced the synaptic localization
of NMDA receptor clusters compared to controls (Fig. 2A, C), consistent with the overall
decrease in surface NMDA receptor cluster density (Fig. 1). Since patients who receive
early treatment often fully recover, we investigated whether the antibody-mediated
decrease in NMDA receptor synaptic localization was reversible. Patient antibodies were
removed from the culture medium after 3 days of treatment and neurons were cultured for
4 additional days. The density of synaptically localized NMDA receptor clusters
returned to baseline levels 4 days after patient antibodies were removed (Fig. 2A, C).
These results show that patients’ antibodies cause a specific loss of NMDA receptors
from excitatory synapses and that this loss is reversed after antibody removal.

Patients’ antibodies selectively decrease synaptic NMDA currents
We next assessed the effects of patient antibodies on NMDA receptor function
using whole-cell patch recordings of miniature excitatory postsynaptic currents
(mEPSCs), which consist of a fast AMPA receptor-mediated current and a slow NMDA
receptor current. Neurons were treated for 1 day with patient or control CSF and
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spontaneous inward currents were recorded at -70 mV in a 0 Mg2+ extracellular solution
to unmask synaptic NMDA receptor-mediated mEPSCs. CNQX was used to block
AMPA receptor-mediated mEPSCs and APV was used to block NMDA receptormediated mEPSCs (Fig. 3A).
Patient antibody treatment did not affect mEPSC frequency or amplitude (Supp.
Fig. 4), consistent with structural analyses that showed that patients’ antibodies do not
affect the number of excitatory synapses (mEPSC frequency) or the number of
postsynaptic sites containing AMPA receptors (mEPSC amplitude).
In neurons treated for 1 day with CSF from control patients, CNQX blocked
large, fast AMPA receptor mediated currents, revealing small, slower NMDA receptor
mediated currents that were completely blocked by APV (Fig. 3A, left). In contrast, in
neurons treated for 1 day with patient CSF, CNQX blocked all mEPSCs, and no further
reduction was observed after APV (Fig. 3A, right). This result shows that there is very
little NMDA receptor mediated current in neurons treated with patient antibodies.
To quantify the reduction in synaptic NMDA receptor mediated currents, currents
were examined before and after APV application. In neurons treated for 1 day with CSF
from control patients, APV reduced or abolished the late, slow NMDA receptor mediated
component of the mEPSC (Fig. 3B, left; 3C, left). In contrast, in neurons treated for 1
day with patient CSF, APV application did not further reduce the NMDA receptor
mediated component of the mEPSC (Fig. 3B, right; 3C, left). No difference was
observed in the peak AMPA receptor mediated component of the mEPSC (Fig. 3C,
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right). These results show that patients’ antibodies specifically decrease synaptic
NMDA receptor mediated currents and do not affect AMPA receptor mediated currents,
consistent with the specific loss of surface, synaptically localized NMDA receptor
clusters.

Patients’ antibodies crosslink and internalize NMDA receptors
We next determined the mechanism by which patient antibodies decrease surface
NMDA receptor cluster density and protein. The Fc IgG domain was enzymatically
removed from patients’ antibodies to generate Fab fragments. These Fab fragments, like
intact patient IgG, bound to surface NR1 clusters identified with commercial anti-NR1
immunostaining (Supp. Fig. 5). Neurons were treated for 1 day with patients’ antibody
Fab fragments had the same NMDA receptor cluster density and surface protein as
neurons treated with control IgG (Fig. 4A, B). In contrast, neurons treated for 1 day with
patients’ Fab fragments and anti-Fab secondary antibodies (linking two Fab fragments in
a confirmation similar to unmodified patients’ antibodies) had significantly lower NMDA
receptor cluster density and surface protein as compared to neurons treated with control
IgG (Fig. 4A, B). These results show that patients’ antibodies mediate the loss of surface
NMDA receptors in part by binding to, capping and crosslinking NMDA receptors,
resulting in their internalization (Fig. 4C).
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Patients’ antibodies decrease NMDA receptor cluster density and protein in rodent
and human hippocampus in vivo
Our results show that, in vitro, patients’ anti-NR1 antibodies lead to a selective
loss of surface NMDA receptor clusters and their function, without loss of other synaptic
components or neuron viability. To determine the effects of patients’ antibodies in vivo,
CSF from patients with high titers of NR1 antibodies, or control CSF from individuals
without NR1 antibodies, was infused directly into the hippocampus of adult rats for two
weeks, followed by immunostaining for human IgG to examine the diffusion and
deposition of patients’ antibodies, immunostaining and Western blot analysis of NMDA
receptors and other synaptic components to determine the effects of patients antibodies,
and assessment of cell death using the TUNEL assay. Patient antibodies colocalized with
NMDA receptor clusters in vivo as in vitro (Supp. Fig. 7). Moreover, infused patient
IgG, but not control IgG, was found bound to rat hippocampus in a predictable pattern
that was dependent on NMDA receptor density (e.g., high density in proximal dendrites
of dentate gyrus, data not shown). This pattern was similar to the direct immunostaining
of bound IgG reported in the autopsy of two patients with anti-NMDA receptor
encephalitis (Dalmau et al., 2007).
Patients’ CSF infusion into rat hippocampus caused deposition of human IgG in
the hippocampus (Supp. Fig. 8). Moreover, in regions where human IgG was deposited,
there was a significant decrease in NMDA receptor cluster density and intensity of NR1
immunostaining without affecting the number of synapses, the density of other synaptic
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components (Fig. 5A-E; Supp. Fig. 8) or cell death (Supp. Fig. 8). The magnitude of the
effects of each patient’s CSF correlated with the titer of NR1 antibodies infused into rat
brains (Fig. 5B), as demonstrated in in vitro studies (Fig. 1). Furthermore, the total
amount of NR1 protein was reduced in rodent hippocampus infused with patient
compared to control CSF (Fig. 5C).
To investigate whether NMDA receptor cluster density is reduced in the brains of
patients with anti-NMDA receptor antibodies, paraffin-embedded sections of the
hippocampus of two patients with anti-NMDA receptor encephalitis and the hippocampus
of three age-matched, anti-NR1 negative, neurologically normal individuals were
immunostained with anti-NR1 antibodies. The density of NMDA receptor clusters was
substantially decreased in patients’ hippocampus compared to controls (Fig. 5F-H).
Moreover, deposits of human IgG, but not complement, were identified in some of the
regions with reduced NMDA receptor clusters (data not shown). These data show that
patient anti-NMDA receptor antibodies reduce NMDA receptor cluster in rodent neurons
in vitro and in vivo as well as in patient brain.
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Discussion
Anti-NMDA receptor encephalitis is a recently described disorder that is
associated with antibodies against the NR1 subunit of the NMDA receptor and results in
a well defined set of symptoms. Our previous studies noted that the resulting syndrome
resembled the phenotype of animals in which the NMDA receptor function had been
attenuated pharmacologically or genetically, suggesting that patients’ antibodies
decreased NMDA receptor levels. We now demonstrate using in vitro and in vivo studies
that patients’ antibodies decrease the surface density and synaptic localization of NMDA
receptor clusters via antibody mediated capping and internalization, independent of the
presence of complement, and without affecting other synaptic proteins, AMPA receptors
or synapse density. The magnitude of these changes depends on antibody titer, and the
effects are reversible when the antibody titer is reduced. Moreover, patients’ NR1
antibodies decrease NMDA, but not AMPA, receptor mediated synaptic currents. Thus
the selective loss of surface clusters abolishes NMDA receptor mediated synaptic
currents. These findings indicate that NR1 antibodies from patients with anti-NMDA
receptor encephalitis decrease glutamatergic synaptic function without a substantial loss
of synapses.
This reversible loss of NMDA receptors, and the resulting synaptic dysfunction,
may underlie the deficits of memory, behavior and cognition that are hallmarks of antiNMDA receptor encephalitis (Dalmau et al., 2008). Indeed, a remarkable feature of this
disorder is the frequent reversibility of symptoms, even when these are severe and
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protracted. Previous studies showed a correlation between clinical outcome and antibody
titer, which is usually higher in CSF than serum due to intrathecal antibody synthesis.
The work we present here demonstrates that the effect of patients’ CSF on surface
NMDA receptors is correlated with the change of antibody titers and symptom severity
during the course of the disease. When comparing different patients, a similar correlation
was found between CSF antibody titers and the intensity of effects on NMDA receptors,
but there was inter-patient variability between antibody titers and severity of patients’
symptoms (data not shown). This variability is common to most autoimmune disorders,
and is likely due to patient-specific related factors (e.g., age, fever, poorly controlled
seizures) and the fact that analysis of CSF provides the closest, though imperfect,
assessment of the immune response within the brain. In the current study, analysis of the
hippocampus of two patients who died of this disorder showed a substantial decrease of
NMDA receptor levels compared with the hippocampus of three age-matched,
neurologically normal individuals. This decrease of NMDA receptors was comparable to
that observed in rats infused with patients’ antibodies. Moreover, we previously reported
that patients’ hippocampus showed deposits of IgG and absence of complement (Dalmau
et al., 2007), consistent with the complement-independent antibody effects demonstrated
in in vitro studies.
In the peripheral nervous system, immune-mediated disruption of synaptic
structure and function results in well known disorders of neuromuscular transmission
such as myasthenia gravis and Lambert-Eaton syndrome (Sanders, 2002; Conti-Fine et
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al., 2006). Anti-NMDA receptor encephalitis provides a new model of central nervous
system synaptic autoimmunity, antigenically different but mechanistically similar to
Lambert-Eaton syndrome in which autoantibodies, but not monovalent Fab fragments,
crosslink and internalize voltage-gated calcium channels, without complement activation.
Both disorders may occur as paraneoplastic manifestation of a tumor that expresses
neuronal proteins (e.g., small-cell lung cancer in Lambert-Eaton) or contains ectopic
nervous tissue (e.g., teratoma in anti-NMDA receptor encephalitis). Moreover, in both
disorders the immunological trigger of cases without tumor association is unknown,
although a genetic predisposition to autoimmunity has been demonstrated or suggested.
Although both disorders respond to immunotherapy and when appropriate tumor
removal, the response of anti-NMDA receptor encephalitis is slower and less predictable,
particularly in cases with delayed diagnosis or without a detectable tumor. These patients
usually have persistently high CSF antibody titers, despite the effectiveness of plasma
exchange or IVIg in reducing serum antibody titers. In these cases, symptoms frequently
respond to cyclophosphamide, which crosses the blood-brain barrier, or rituximab, which
depletes memory B-cells. As postulated in other disorders, these cells are able to cross the
blood-brain-barrier, and are believed to undergo re-stimulation, antigen-driven affinity
maturation, clonal expansion, and differentiation into antibody-secreting plasma cells.
NMDA receptor dysfunction has been implicated in several other cognitive
disorders, including schizophrenia (Olney and Farber, 1995). Studies investigating the
effects of phencyclidine and ketamine (noncompetitive antagonists of NMDA receptors)
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in human subjects show these drugs induce behaviors similar to the positive and negative
symptoms of schizophrenia, along with repetitive orofacial and limb movements,
autonomic instability, and seizures (Luby et al., 1959; Krystal et al., 1994). In rodents,
drugs that antagonize NMDA receptor function induce cataleptic freeze, and locomotor
and stereotype behaviors, consistent with schizophrenia-like manifestations (Jentsch and
Roth, 1999; Mouri et al., 2007). Furthermore, mice with decreased expression of NR1
have similar behavioral deficits, while mice lacking NR1 develop breathing problems and
die in the perinatal period (Mohn et al., 1999). Interestingly, most patients with antiNMDA receptor encephalitis present with acute schizophrenia-like symptoms and are
admitted to psychiatric institutions before they develop catatonia, catalepsy, stereotyped
movement disorders, and frequent autonomic instability and hypoventilation. The striking
similarity between these phenotypes, the effect of patients’ antibodies resulting in a
dramatic decrease of surface NMDA receptor clusters and function, and the reduced
levels of NMDA receptors in autopsied patients, support an antibody-mediated
pathogenesis of anti-NMDA receptor encephalitis. The psychosis and cognitive and
behavioral deficits in patients with anti-NMDA receptor encephalitis most likely result
from NMDA receptor hypofunction, directly and indirectly affecting synapse and circuit
structure and function in regions that bind anti-NR1 autoantibodies. Thus the findings we
report here also support the hypothesis that NMDA receptor hypofunction underlies
many manifestations of schizophrenia. Future studies will focus on the circuit-level
dysfunction caused by patient antibodies in hippocampus and other brain regions, to
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begin to connect synaptic and circuit dysfunction with the behavioral abnormalities that
are hallmarks of this disorder.
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Materials and Methods
Preparation of patient and control CSF and IgG
Patient or control cerebrospinal fluid (CSF) was collected and filtered using
protein A/G sepharose columns. CSF was diluted 1:15-50 to treat neurons in vitro. In
some experiments, IgG purified from serum was used to treat neurons (Fig. 1D, F; Fig.
4). Both patient CSF and patient IgG decreased surface and total NMDA receptors to the
same extent (Supp. Fig. 6). Furthermore, the effects of patient CSF on NMDA receptor
cluster density were not mediated by complement, because heat-inactivated patient CSF
decreased NMDAR cluster density and localization to a similar extent as non-heat
inactivated patient CSF (Supp. Fig. 6). Briefly, 10 ml of patient or control serum were
incubated with a 5 ml column of protein A/G Sepharose beads (50:50) for 30 min. on an
orbital shaker at 4 °C. After elution IgG was added to a bio-spin chromatography column
(Bio-Rad) followed by 3 washes with PBS, eluted with 100 mM glycine, pH = 2.5 and
neutralized with Tris-HCl, pH = 8.0, dialyzed against PBS and concentrated to stock
solutions of 20 mg/ml and stored at -80 °C. IgG concentration (~1mg / ml) and pH (7.4)
were adjusted prior to use. Each CSF or IgG preparation was tested for antibody
reactivity by staining mouse or rat brain sections or HEK cells expressing NR1/NR2
heteromers of the NMDAR as previously described (Dalmau et al., 2007; Dalmau et al.,
2008).

Cell culture and patient antibody treatment
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Primary rat hippocampal neuron and astrocyte cultures were prepared from
embryonic day 18-19 (Goslin et al., 1988). Briefly, hippocampi were in Ca2+ free HBSS
containing 1% papain for 20 min., triturated in Basal Media Eagle (BME; Invitrogen)
supplemented with B-27 (Life Technology) and plated at 100,000 or 400,000 (for
biotinylation) cells per ml in Neural Basal (NB; Life Technologies) supplemented with
10% FBS (Hyclone), B-27, 1% penicillin and streptomycin (Life Technologies) and 1%
L-Glutamine (Life Technologies) on poly-L-lysine coated (Sigma) coverslips in 24-well
plates. Culture media was changed to NB supplemented with B27 at 4 div. Cells were
maintained at 37 °C, 5% CO2, 95% humidity; medium was changed weekly.

Immunostaining for pre- and postsynaptic components
To stain surface NMDAR clusters, control or treated neurons were washed in NB
plus B27 and were incubated with patient CSF containing anti-NR1 antibodies for 30
min., washed and incubated with fluorescently conjugated anti-human secondary
antibodies for 30 min., and washed in PBS. Neurons were then fixed in 4%
paraformaldehyde, 4% sucrose in PBS, pH = 7.4 for 15 min., permeabilized with cold
0.25% Triton X-100 for 5 min., and blocked in 5% normal goat serum (Invitrogen) for 1
hour at RT. Additional immunostaining was performed with various combinations of
primary antibodies: to label glutamate receptors, anti-NR1 (1:1000; Chemicon), antiGluR1 (1:10; CalBioChem) or anti-GluR2/3 (1:100; Chemicon); to label dendrites,
chicken anti-MAP2 (1:5000; AbCam); to label presynaptic terminals, mouse anti-SV2
118

(1:200; DHSB); guinea pig anti-VGLUT 1 (1:5000; Chemicon), or mouse anti-Bassoon
(1:400; Stressgen Bioreagents). Antibodies were visualized after staining with the
appropriate fluorescently conjugated secondary antibodies (1:200, Jackson
ImmunoResearch).

Confocal imaging, image analysis and statistical analysis
For all experiments, 6-12 randomly selected pyramidal neurons, identified by
morphology (Elmariah et al., 2004; Elmariah et al., 2005) in each condition were imaged
using confocal microscopy (Leica TCS 4D system) on each of 2-3 coverslips in 3-5
independent experiments. Images were thresholded automatically using an iterative
thresholding technique (Bergsman et al., 2006), and the number and area of individual
immunostained pre- or postsynaptic clusters were determined using interactive software
(custom-written ImageJ macros). Clusters with more than 20% pixel overlap of pre- and
postsynaptic markers were considered colocalized and thus synaptic. Cluster density was
compared among conditions using the Kruskal-Wallis nonparametric ANOVA test
followed by Dunn’s pairwise multiple comparison test, unless otherwise indicated. All
values are presented as mean ± s.e.m.

Biotinylation of surface proteins and analysis by Western blot
Neurons were treated with 1 μg – 1 mg/ml IgG for 1 day, washed with PBS
supplemented with 0.1 mM CaCl2 and 1 mM MgCl2 (rinsing buffer) and incubated for 30
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min. at 4 °C with 1 mg/ml Sulfo-NHS-Biotin (Thermo Scientific) in rinsing buffer.
Neurons were then washed with rinsing buffer + 100 mM glycine (quenching buffer),
incubated in quenching buffer for 30 minutes at 4°C to quench excess biotin, then lysed
in RIPA buffer (150 mM NaCl, 1 mM EDTA, 100 mM Tris HCl, 1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS, pH 7.4, supplemented with 1:500 protease inhibitor
cocktail III, Calbiochem) at 4 °C for 1 hour. Lysates were cleared of debris by
centrifugation at 12400 x g for 20 min. An aliquot of the remaining supernatant was taken
for the lysate fraction, and a second aliquot was incubated with avidin-linked agarose
beads (Immobilized Monomeric Avidin, Thermo Scientific) overnight at 4 °C. After
centrifugation, the supernatant was removed and the beads (surface fraction) were
washed 1X RIPA buffer, 2X high-salt wash buffer (500 mM NaCl, 5 mM EDTA, 50 mM
Tris, 0.1% Triton X-100, pH 7.5), and 1X no-salt wash buffer (50 mM Tris, pH 7.5). The
surface fraction was eluted from the beads with 2X sample buffer and proteins separated
on an 8% gel using SDS-PAGE. Samples were transferred to nitrocellulose membranes
and probed for antibodies against NR1 (1:1000, 556308, BD Pharmingen), NR2A
(1:1000, AB1555, Millipore; 1:500, MAB5216, Millipore; 1:500, A6473, Invitrogen),
NR2B (1:1000, AGC-003, Alomone; 1:500, 06-600, Upstate), GABAARα1 (1:1000, 06868, Upstate), GABAARα2 (1:500, AB5984, Chemicon), GluR 2/3 (1:1000, 07-598,
Upstate), PSD-95 (1:1000, 610496, BD Pharmingen), and actin (1:2000, A2066, Sigma).
Actin and GABAARs were used as loading controls for total and surface fractions,
respectively. Blots were incubated with HRP-conjugated goat anti-mouse or goat anti120

rabbit secondary antibodies (1:3000, Cell Signaling), and signals were visualized using
chemiluminescence (SuperSignal Chemiluminescent Substrate, Thermo Scientific). All
quantified films were in the linear range of exposure, were digitally scanned and signals
quantified using NIH ImageJ.

Whole cell electrophysiological recordings of synaptic NMDA and AMPA receptor
mediated currents
Whole cell voltage clamp recordings were performed as previously described
(Elmariah et al., 2004; Elmariah et al., 2005) from 14 – 21 div pyramidal neurons treated
for 24-48 hours with patient CSF containing anti-NR1 antibodies, control CSF or left
untreated. Briefly, neurons were incubated in extracellular physiology solution without
Mg2+ (in mM: 119 NaCl, 5 KCl, 2 CaCl2, 30 Glucose, 10 HEPES, pH = 7.4). Voltageclamp recordings were made at RT (22-25 °C) using glass microelectrodes (resistance 46 MΩ) filled with a Cesium substituted intracellular solution (in mM: 100 Cesium
gluconate, 0.2 EGTA, 5 MgCl2, 2 ATP, 0.3 GTP, 40 HEPES, pH = 7.2). Pipette voltage
offset was neutralized before the formation of a gigaohm seal. Membrane resistance,
series resistance, and membrane capacitance were determined from current transients
elicited by a 5 mV depolarizing step from a holding potential of -80 mV, using the whole
cell application of HEKA software. Criteria for cell inclusion in the data set included a
series resistance ≤ 30 MΩ and stability throughout the recording period. Currents were
amplified, low-pass filtered at 2.5 kHz, and sampled at 5 Hz using HEKA software.
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Miniature excitatory spontaneous currents (mEPSCs) were recorded at -70mV in the
presence of TTX (1 µM) and Picrotoxin (10 µM). APV (50 µM) and CNQX (10 µM)
were bath applied to block NMDAR and AMPAR mediated currents respectively.
mEPSC events were detected and analyzed using MiniAnalysis (Synaptosoft, Leonia,
NY), which employs a threshold-based event-detection algorithm. NMDAR and
AMPAR components of mEPSCs were separated temporally by their distinct kinetics
(Hestrin et al., 1990; Watt et al., 2000; Yang et al., 2003). The amplitude of the NMDAR
mediated current was determined in a window between 15 and 25 ms after the peak of the
AMPAR mediated component, which has a fast, < 1 ms rise time. All values are
presented as mean ± s.e.m.

Fab fragments preparation and treatment
Fab fragments were prepared from serum IgG using a kit according to the
manufacturer’s directions (Fab preparation kit, Pierce Protein Research Products, Thermo
Scientific). Briefly, serum IgG was digested for 2-4 hours at 37 °C with 1% (w/w)
papain pH= 7.0 with 0.01 M cysteine, resulting in cleavage into Fab and Fc fragments.
Fab fragments were then isolated by chromatography and concentration determined by
absorption at 280 nm. Fab fragments were used to treat neurons at a concentration of 4
μg/ml. Control experiments showed that incubating neuron with patient Fab fragments
for 30 min. resulted in surface staining of NR1 clusters (Supp. Fig. 5).
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Alzet mini-pump placement, IgG infusion and sectioning
Young adult rats (6-8 weeks old) were anesthetized and a cannula placed into the
left lateral ventricle using predetermined coordinates (AP 0.6 mm, lateral 1.6 mm to
bregma and horizontal 2.0 mm to the dura mater). The cannula was attached to a head
probe mounted to the skull. The cannula was attached to an Alzet minipump (Alzet brain
infusion kit #3, pump model 2002) placed subcutaneously on the back and attached to the
head probe via sterile tubing. Patient or control CSF was then delivered at a rate of 0.5 μl
/ hr for 2 weeks. Rats were then euthanized, brain tissue harvested, immersion fixed in
4% paraformaldehyde in PBS, pH = 7.4 for 15 min., cryoprotected in 30% sucruose in
PBS, pH = 7.4 overnight at 4 °C, frozen in isopentane cooled in dry ice, and frozen
sections obtained at 20 μm. Sections were immunostained using one or more of the
primary and fluorescent secondary antibodies, confocally imaged and images thresholded
and analyzed as described above.
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Figure Legends

Figure 4.1 Patient antibodies reduce surface NMDA receptor clusters and protein
in a titer dependent fashion.
(a) Hippocampal neurons immunostained for surface, total NMDA receptor
clusters and the presynaptic terminal marker Bassoon. Treatment with patient CSF for 1
day reduces the density of surface and total NMDA receptors without affecting
presynaptic terminal density. Scale bar = 10 μm. (b) Immunoblots of surface and total
NMDA receptor protein. Treatment with patient IgG (isolated from serum) reduces
surface as well as total NMDA receptor protein. GABAAα1 or actin are loading controls
for the surface and total protein, respectively. Control NR1 levels have been overexposed
in this image to visualize patient treated NR1 bands. (c) Quantification of surface (left)
and total (right) NMDA receptor clusters after treatment with CSF from several patients
with different antibody titers. CSF from patients with higher titer decrease surface and
total NMDA receptor clusters to a greater extent. (d) Quantification of surface (left) and
total (right) NMDA receptor protein after treatment with IgG from the same patient at
two timepoints with different antibody titer. IgG isolated from patients with a higher
antibody titer decreased surface and total NMDAR protein to a greater extent than IgG
isolated from the same patient when a lower antibody titer was present.
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Figure 4.2 Patient antibodies reversibly reduce synaptic NMDA receptor clusters
without affecting the number of synapses.
(a) Hippocampal neurons immunostained for total NMDA receptor clusters, a
presynaptic glutamatergic terminal protein, VGlut, and a postsynaptic protein localized to
glutamatergic synaspes, PSD-95. Treatment with patient CSF for 1 day reduces the
density of synaptic NMDA receptor clusters without affecting the number of excitatory
synapses. After removal of patient CSF, the proportion of NMDA receptor clusters
localized to synapses returns to baseline. Scale bar = 10 μm. (b) Quantification of the
colocalization of pre- and postsynaptic proteins at excitatory synapses. (c) Quantification
of the density of NMDA receptor clusters at excitatory synapses (synaptic NR1).
Asterisk indicates significant difference (Student’s t test, p < 0.001).
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Figure 4.3 Patient antibodies selectively decrease synaptic NMDA currents.
(a) mEPSCs recorded in physiological saline with TTX, bicuculline, and 0 Mg2+
to isolate synaptic NMDA receptor mediated currents (left upper trace). APV, an NMDA
receptor antagonist, blocks the slow decay of mEPSCs leaving only AMPA receptor
mediated currents which account for the fast rise of mEPSCs (left upper middle trace).
CNQX, an AMPA receptor antagonist, blocks the fast rise of mEPSCs, allowing NMDA
receptor mediated currents to be isolated, as indicated by asterisks (left lower middle
trace). Both AMPA and NMDA receptor mediated synaptic currents are blocked by
CNQX plus APV (left bottom trace). Treatment of hippocampal neurons with patient
CSF for 1 day dramatically reduces synaptic NMDA receptor mediated currents (right).
(b) Representative average mEPSCs from neurons treated for 1 day with control CSF
(left) or patient CSF (right). APV does not affect the slow decay of mEPSCs in neurons
treated for 1 day with patient CSF, indicating that patient antibodies decrease NMDA
receptor mediated synaptic currents. (c) Quantification of the effect of patient antibodies
on NMDA (left) and AMPA (right) receptor mediated synaptic currents (right). Asterisk
indicates significant difference (Student’s t test, p < 0.001).
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Figure 4.4 Patient antibodies bind, crosslink and internalize NMDA receptors.
(a) Hippocampal neurons immunostained for surface and total NMDA receptor
clusters. Treatment with patient IgG decreases and total NMDA receptor cluster density
(middle left). Treatment with patient Fab fragments does not affect surface or total
NMDA receptor cluster density (middle right), while treatment with reclustered patient
Fab fragments decreases surface and total NMDA receptor cluster density (right). Scale
bar = 10 μm. (b) Quantification of the effects of patient IgG, Fab fragments, and
reclustered Fab fragments on surface and total NMDA receptor cluster density. Asterisk
indicates significant difference (Student’s t test, p < 0.001). (c) Schematic which
outlines the effect of each treatment on surface receptor clusters.
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Figure 4.5 Patients’ antibodies decrease NMDA receptor cluster density and protein
in rodent and human hippocampus in vivo.
(a) After implanting a cannula into the CA1 region of hippocampus and infusing
control or NMDA patient CSF at a rate of ~0.5 µl/hour for 8 days, rats were euthanized,
frozen hippocampal sections prepared and immunostained with synaptic antibodies. Brain
sections from rats infused with control CSF (top left) contain bright and clustered NMDA
receptor staining in CA1, while brain sections from rats infused with patient CSF (top
right) contain significantly reduced NMDA receptor staining. Staining for synapsin, a
presynaptic terminal protein, is similar between control CSF and patient CSF injected rats
(bottom left, right). Scale bar = 2 µm. (b) Quantification of the effect of infusion of
patient CSF with varying antibody titer on NMDA receptor cluster density in CA1.
Patient CSF with higher antibody titers reduce NMDA receptor cluster density to a
greater extent than low titer samples. (c) Western blot analyses of NR1 protein in control
and patient CSF infused rat hippocampus, ipsilateral (I) and contralateral (C) to infusion.
NR1 protein is reduced in ipsilateral patient CSF infused hippocampus. (d)
Quantification of the density of synapsin labeled clusters (Student’s t test, p > 0.5). (e)
Quantification of the density of excitatory synapses (colocalization between presynaptic
synapsin and postsynaptic AMPA receptor clusters (Student’s t test, p > 0.5). (f)
Hippocampal tissue section from a control patient (left) and from patient with antiNMDA receptor encephalitis (right) immunostained with a commercial anti-NR1
antibody. The intensity of NR1-immunoreactivity is dramatically reduced in the
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hippocampi of anti-NMDA receptor encephalitis patients (N = 2) compared to
hippocampi of control patients (N = 3). (g) Boxed areas in f shown at higher
magnification. Scale bars = 1 mm (top); 25 μm (bottom). (h) Quantification of the
intensity of NR1 immunostaining (Student’s t test, p < 0.001).
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Supplemental Figure 4.1 Patient IgG treatment decreases surface and protein of
NMDA receptor NR2A/B subunits in a titer dependent fashion.
(a) Immunoblots of surface and total NMDA receptor NR2A and NR2B protein.
Treatment with patient IgG reduced surface as well as total NMDA receptor NR2A
protein. GABAAα1 and actin are loading controls for surface and total protein,
respectively. (b) Quantification of surface (left) and total (right) NMDA receptor NR2A
protein after treatment with IgG from several patients with different antibody titer. IgG
from patients with higher titer resulted in a greater decrease in surface and total NMDA
receptor NR2A and NR2B protein than patients with a lower titer. (c) Quantification of
surface (left) and total (right) NMDA receptor NR2B protein after treatment with IgG
from several patients with different antibody titer. IgG from patients with higher titer
resulted in a greater decrease in surface and total NMDA receptor NR2B protein than
patients with a lower titer.

136

137

Supplemental Figure 4.2 Patient CSF treatment does not affect other synaptic
components.
(a) Hippocampal neurons immunostained for an excitatory postsynaptic protein,
PSD-95, excitatory presynaptic protein, VGlut, and surface clusters of AMPA receptor
subunits GluR1 or GluR2. Scale bar = 10 μm. (b) Quantification of excitatory synaptic
protein density. Treatment with patient CSF did not affect the density of these excitatory
synaptic proteins. (c) Immunoblots of excitatory postsynaptic proteins, AMPA receptor
subunits GluR2/3, excitatory postsynaptic protein PSD-95 and GABAA receptors.
Treatment with patient IgG did not affect surface or total neurotransmitter receptor or
excitatory synapse protein levels.
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Supplemental Figure 4.3 Patient CSF treatment does not affect dendritic spines or
branching.
(a) Hippocampal neurons transfected with the fluorescent protein, Tomato-td,
imaged before and after one day of treatment with control or patient CSF, and traced with
NeuronJ. Control (top) or patient (bottom) CSF treatment did not affect dendritic
branching or complexity. Scale bar = 100 μm. (b) Quantification of primary dendrite
number. (c) Quantification of primary dendrite length (Student’s t test, p > 0.05). (d)
Sholl analysis of dendrite complexity before (white) and after (black) one day of control
(left) or patient CSF (middle) treatment. Comparison of the difference before and after
control and patient CSF treatment (right). (e) Hippocampal neurons transfected with
Tomato-td and treated for one day with control or patient CSF. Control (top) or patient
(bottom) CSF treatment did not affect dendritic protrusion density. Scale bar = 5 μm. (f)
Quantification of the density of dendritic protrusions (Student’s t test, p > 0.05).
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Supplemental Figure 4.4 Patient CSF treatment does not affect mEPSC frequency
or amplitude.
(a) Quantification of mEPSC amplitude in neurons treated with and without
control, patient CSF, and APV. The total mEPSC amplitude (which represents the
amount of functional postsynaptic AMPA receptors) is not significantly different among
control, patient CSF or APV conditions (Kruskal-Wallis nonparametric ANOVA test
followed by Dunn’s pairwise multiple comparison test). (b) Quantification of mEPSC
frequency in neurons treated with and without control, patient CSF, and APV. The
frequency of mEPSCs (which represents the number of excitatory synapses) is not
significantly different between control, patient CSF or APV conditions (Kruskal-Wallis
nonparametric ANOVA test followed by Dunn’s pairwise multiple comparison test).

142

143

Supplemental Figure 4.5 Patient antibody Fab fragments colocalize with NMDA
receptor clusters.
(a) Hippocampal neurons immunostained for NMDA receptor clusters in neurons
treated for 1 day with control IgG (top row), patient IgG (middle top), patient IgG
clustered with anti-Fab secondary antibodies (middle), patient Fab fragments (middle
bottom), patient Fab fragments reclustered with anti-Fab secondary antibodies (bottom).
Color overlays of NR1 (red) and human IgG (green) are shown at right. While patient
IgG and patient IgG + anti-Fab stain neurons more intensely, patient Fab fragments and
patient Fab fragments + anti-Fab colocalize with NMDARs to a similar extent. Scale bar
= 10 μm.
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Supplemental Figure 4.6 Patient IgG and CSF treatment have similar effects and
these effects are not mediated via the complement pathway.
(a) Quantification of hippocampal neurons immunostained for surface NMDA
receptor clusters treated with Control IgG, CSF, patient IgG, CSF, and heat inactivated
patient CSF. Treatment with patient IgG and CSF for one day decrease surface NMDARs
to a similar extent. Heat inactivated patient CSF also decrease surface NMDARs to a
similar extent as patient IgG and CSF, suggesting that these effects are not mediated by
complement-mediated pathways. (b) Quantification of dissociated hippocampal neurons
immunostained for total NMDARs treated with Control IgG, CSF, patient IgG, CSF, and
heat inactivated patient CSF (Kruskal-Wallis nonparametric ANOVA test followed by
Dunn’s pairwise multiple comparison test)
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Supplemental Figure 4.7 Patient CSF recognizes NMDA receptor clusters in vivo.
(a) Rat brain sections immunostained with patient CSF (top left), NMDA
receptors (top middle), and a postsynaptic protein, PSD-95 (top right). Patient CSF
clusters are highly colocalized with NMDARs (yellow puncta, bottom left). Patient CSF
clusters colocalize with PSD-95 to a similar extent as NMDARs (compare bottom middle
to bottom right).
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Supplemental Figure 4.8 Infusion of patient CSF results in the deposition of human
IgG in the hippocampus without increasing cell death.
(a) Brain sections from rats infused with control (left) or patient CSF (right) into
one hippocampus, and immunostained with human IgG, NR1, and TO-PRO to label
nuclei. The deposition of human IgG was seen in the hippocampus of rats infused with
patient CSF but not control CSF. Below, higher magnification views of the CA1 region
of the hippocampus show that areas with human IgG deposits have reduced NMDA
receptor clusters (see Fig. 5) and decreased overall staining intensity. (b) Brain sections
from rats infused with control or patient CSF and immunostained with NR1 to label
NMDA receptors, TO-PRO to label nuclei, and TUNEL to label apoptotic cells. Infusion
with control (left) or patient CSF (middle) did not cause significant cell death. While
several apoptotic cells were found along the cannula tract (right), the total number and
distribution did not differ between rats infused with control or patient CSF. (b)
Quantification of the density of dissociated hippocampal cells in vitro between control or
patient CSF treatment (left) and of the percent of TUNEL positive neurons in vitro
(apoptotic cells). These measures were not significantly different between control or
patient CSF treatment (Student’s t test).
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Conclusions

The work described in the previous chapters extends our understanding of how
neuron-glia signaling modulates GABAergic synapse formation in the developing CNS
and how autoantibodies in patients with anti-NMDAR encephalitis disrupt synapse
maintenance in the diseased nervous system. In particular, I have demonstrated that
proteins secreted from astrocytes specifically increase GABAergic axon length, branch,
and synaptogenesis and identified the astrocyte soluble proteins in size fractions that
promote these effects. I have also shown that antibodies from anti-NMDAR encephalitis
patients reversibly alter the number and distribution of glutamate receptors in neurons,
resulting in a decrease in excitatory synapse function which most likely underlies the
cognitive dysfunctions that characterize this immune-mediated encephalitis. Thus, these
findings extend our understanding of how neuron-glial communication modulates the
formation of synapses and how the disruption of synapse maintenance may underlie
cognitive deficits in the diseased nervous system.
This work raises important questions for future research into the formation of
GABAergic synapses. First, the differential regulation of glutamatergic and GABAergic
synaptogenesis by astrocytes (Chapter 2) highlights the need for more in depth research
into the mechanisms underlying synapse formation of different cell types. Recent work
identifying transcription factors and secreted and cell adhesion molecules that specifically
regulate GABAergic synapse development (Paradis et al., 2007; Ango et al., 2008; Lin et
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al., 2008) has set the stage for understanding how astrocytes differentially modulate
glutamatergic and GABAergic synaptogenesis. Second, the generation of a transgenic
mouse model with astrocytes in which exocytosis is deficient (Pascual et al., 2005)
provides a new tool to begin to examine the mechanisms governing the release of
proteins from astrocytes that affect GABAergic neurons and synapses. Since astrocyte
calcium elevations have been implicated in mediating the release of transmitters from
astrocytes that affect neurons (Scemes and Giaume, 2006)); but also see ((Fiacco et al.,
2007), it will also be important to investigate how astrocyte activity may play a role in
the release of proteins that increase GABAergic synaptogenesis. Third, studies have
shown that astrocytes from different regions differ in their ability to modulate neurite
outgrowth (Qian et al., 1992), therefore it will be important to examine whether local
astrocytes support synaptogenesis in a manner distinct from target-derived or other cues.
In addition, it will be important to evaluate the ability of both immature and mature
astrocytes to affect GABAergic neurons. Recent work has shown that only immature
astrocytes express thrombospondins, which have been shown to increase excitatory
synaptogenesis (Christopherson et al., 2005). This future work will be critical to
understanding how astrocytes modulate synaptic connections in the developing and
mature brain and will ultimately contribute to neurodevelopmental disorders such as
epilepsy, autism and mental retardation, in which synapse formation, function,
maintenance are aberrant or reduced.
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The identification of proteins contained within gel filtration fractions that increase
GABAergic axon length, branching, and synaptogenesis (Chapter 3) lays the foundation
for several future experiments, with the ultimate goal of evaluating the effects of
astrocytes on the development of GABAergic synapses in vivo. The 34 candidates
identified in the bioactive fractions of astrocyte conditioned media can be individually
tested by treating neuron only cultures with three different concentrations of the
recombinant protein for three days. These cultures will be immunostained for GAD and
VGAT to identify GABAergic neuron neurite morphology and presynaptic terminal
density. In this manner, these candidates can be evaluated in a relatively short period of
time. Once a candidate is confirmed in these in vitro assays, the role of that candidate in
mediating the effects of astrocytes in vivo can be examined using transgenic and knockout mouse models. Recently, several groups have used different approaches to identified
single candidates or families of proteins from large groups of potential candidates
(Kurusu et al., 2008; Linhoff et al., 2009). These approaches and others will be necessary
as proteomic and genomic techniques provide increasingly detailed information about the
processes that underlie synapse formation and development.
The identification of cellular mechanisms underlying anti-NMDAR encephalitis
(Chapter 4) raises many important questions for future research into this and another
diseases that cause synapse dysfunction. The most important future goal is to confirm the
repertoire of pathogenic affects of autoantibodies in in vivo models of anti-NMDAR
encephalitis. The generation of an animal model with similar features of the human
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disease, including production of autoantibodies and disruption of blood-brain barrier
integrity to allow antibodies access to the CNS, will allow further examination of the key
mechanisms of this disorder. One issue of interest is to determine what effect antiNMDAR autoantibodies have on hippocampal circuit plasticity, in particular LTP and
LTD, and to attempt to directly relate this to behavior in in vivo models. It will also be
essential to investigate the immunological mechanisms of disease onset, in particular to
understand the parameters that affect continued intrathecal production of antibodies
observed in patients with this and related disorders. Research into new treatments that
may interfere with the pathogenic properties or actions of autoantibodies against the
NMDA receptors will help provide better outcomes to patients. Ultimately, understanding
the cellular, synaptic and circuit mechanisms and consequences of anti-NMDAR
encephalitis will provide important information that can be leveraged to make progress in
other psychiatric disorders involving glutamate receptor dysfunction, such as
schizophrenia.
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